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Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an ion channel disorder in the 
heart, which is characterized by abnormal calcium handling, ventricular arrhythmias, and sudden 
cardiac death. This inherited disease is predominantly caused by mutations in the ryanodine 
receptor type 2 (RYR2). Most of the identified mutations are clustered into four distinct domains 
of the RYR2 channel. Although heterologous expression systems and animal models have 
brought important insights in the CPVT pathogenesis, the underlying electrophysiological 
mechanisms have not been completely understood. The aim of the study was to take cells from 
CPVT patients with specific RYR2 mutations, to create patient-specific induced pluripotent stem 
cells (iPSCs), to differentiate these cells into cardiomyocytes (CMs) and then to model the 
disease in vitro for a better understanding of the disease mechanism and for the investigation of 
novel therapeutic applications for CPVT patients. 
Somatic cells from skin biopsies of CPVT patients carrying the RYR2 mutation in domain a 
(R420W), domain b (A2254V), domain c (E4076K) or domain d (H4742Y) were isolated and 
reprogrammed into patient-specific iPSCs. The CPVT as well as healthy control (Ctrl) iPSC lines 
were differentiated into CMs. The CPVT- and Ctrl-iPSC-derived CMs were investigated for their 
biological, electrophysiological, and pharmacological differences between the RYR2 mutations 
in different domains and healthy controls. The differences in 3',5'-cyclic adenosine 
monophosphate (cAMP) dynamics were investigated as well. 
Electrophysiological analyses showed that the CPVT-CMs recapitulated the phenotype of CPVT 
both by patch-clamp assessment and by multielectrode array assessment. The single CPVTd-
CMs showed a unique early afterdepolarization (EAD) phenotype in basal condition and 
isoproterenol- (ISO-) challenged condition. However, CPVTa-, CPVTb- and CPVTc-CMs 
exhibited delayed afterdepolarization (DAD) and DAD-induced triggered activities (TAs), which 
were significantly enhanced after the ISO treatment. In the monolayer cultures, all CPVT-CMs 
revealed a significantly increased number of premature ventricular complex- (PVC-) like events 
and prolonged duration of ventricular tachycardia- (VT-) like events after the ISO treatment. In 
contrast, no increased appearance of arrhythmic events (DADs, EADs, DAD- or EAD-induced 





antiarrhythmic drugs (flecainide, dantrolene, rycal1 and rycal2) showed antiarrhythmic effects on 
CPVTa-, CPVTb- and CPVTc-CMs, but no or minor antiarrhythmic effect on CPVTd-CMs. 
FRET measurement revealed that the contribution of phosphodiesterase 2 (PDE2) to cAMP 
degradation in all CPVTa- (15.41%), b- (9.48%), c- (15.07%), d-CMs (7.9%) were significantly 
lower than in Ctrl-CMs (27.5%) in cytosol. The contribution of PDE2 to cAMP degradation at 
the RYR2 compartment in all CPVTa- (14.19%), b- (25.21%), c- (17.32%), d-CMs (8.6%) were 
also significantly lower than in Ctrl-CMs (39.98%). Similar to PDE2, the contribution of PDE3 
to cAMP degradation in all CPVT-CMs were significantly lower than in Ctrl-CMs both in 
cytosol and at the RYR2 compartment. However, for PDE4, there were lower activities in 
cytosol in CPVTb- and CPVTc-CMs when compared to Ctrl-CMs, and  lower activities at the 
RYR2 compartment in CPVTc- and CPVTd-CMs when compared to Ctrl-CMs. Furthermore, the 
data indicate that PDE4 is the major regulator of cAMP level in CPVT-CMs both in cytosol and 
at the RYR2 compartment after ISO stimulation and that PDE2 and PDE3 have a smaller 
contribution to regulate the cAMP level. 
Taken together, this study reveals that mutation-specific CPVT-iPSCs can be used to model the 
disease in vitro, to investigate the disease pathophysiological and molecular mechanisms and to 







1.1 Catecholaminergic polymorphic ventricular tachycardia 
 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is induced by emotional stress 
or physical exercise in patients without structural cardiac abnormalities. This disease was first 
described as a novel clinical entity by Coumel et al. in 1978 (Coumel et al., 1978) and then in a 
follow-up study in 1995 (Leenhardt et al., 1995). 
 
1.1.1 Clinical characteristics 
 
The electrocardiograms (ECG) of CPVT patients are normal when the patient is at rest, but 
become polymorphic, bidirectional ventricular arrhythmias after emotional or physical stress 
(Figure 1). The ventricular arrhythmias sometimes degenerate into ventricular fibrillation, which 
can lead to syncope or sudden cardiac death. The mean age of occurrence of symptoms (usually 
a syncopal episode) of CPVT is between seven and twelve years; occurrence as late as the fourth 
decade of life has been reported. If untreated, CPVT is highly lethal, as approximately 30% of 
affected individuals experience at least one cardiac arrest and up to 80% one or more syncopal 








Figure 1. Typical features of ventricular tachycardia and fibrillation in a patient with CPVT. (A) 
Polymorphic ventricular tachycardia. (B) Bidirectional ventricular tachycardia. (C) Rapid polymorphic 
ventricular tachycardia deteriorating into ventricular fibrillation. These electrocardiograms were 
recorded by Holter monitoring in the CM3 lead in the same patient (Sumitomo, 2015). With permission 
from Elsevier. 
  
1.1.2 CPVT classification 
 
Various genotypes of CPVT have been described, ranging from CPVT1 to CPVT5. The most 
common type of CPVT is caused by a mutation in the ryanodine receptor 2 genes (RYR2) 
(CPVT1), which accounts for 50%-55% of the CPVT cases. The second most common type 
CPVT2 is caused by a homozygous or compound heterozygous mutation in the calsequestrin 2 
gene (CASQ2). Recently, the mutations in the calmodulin gene (CALM1) and triadin gene 
(TRDN) have been found to be responsible for CPVT4 and CPVT5, respectively. So far, no exact 
gene has been identified for CPVT3 (Bhuiyan et al., 2007).  Based on the inheritance patterns, 
CPVTs can be divided into two groups: (1) RYR2- and CALM1-related CPVTs are inherited in an 
autosomal dominant manner, and (2) CASQ2- and TRDN-related CPVTs are inherited in an 





Table 1. Subtypes of CPVT 
 
1.1.3 RYR2 mutations linked to CPVT 
 
The RYR2 channel is the largest ion channel, which contains approximately 5000 residues for 
every homotetramer. Each subunit contains a large cytosolic domain formed by the first ~4300 
N-terminal residues and a smaller transmembrane domain formed by the last ~500 C-terminal 
residues (Priori and Chen, 2011). The transmembrane domain of RYR2 encompasses the channel 
pore whereas the cytosolic domain contains binding sites for a number of channel regulators 
(Mohler and Wehrens, 2007).  
 
Genes 
Proportion of  






































Figure 2. Structural domains and accessory proteins of RYR2. The primary structure of RYR2 and 
its accessory proteins PP1, PP2A, PKA, calmodulin, and FKBP12.6 are shown. PP1,  PP2A and PKA 
bind to RYR2 via their specific adaptor proteins. CaM, calmodulin; LIZ, leucine-isoleucine zipper 
(Mohler and Wehrens, 2007). With permission from American Physiological Society.  
 
The sarcoplasmic reticulum (SR) transmembrane proteins triadin and junctin have been 
associated with the C-terminus of Ryr2 in the SR lumen, anchoring the Ca2+ binding protein 
CASQ2 to Ryr2 to form a quaternary complex, termed “Ca2+ release unit” (Kushnir and Marks, 
2010). The phosphatases 1 and 2a (PP1 and PP2A), Calstabin 2 (FKBP12.6), protein kinase A 
(PKA), Ca2+/calmodulin-dependent kinase II (CaMKII), phosphodiesterase 4D3 (PDE4D3), 
calmodulin protein (CaM), and sorcin are associated with the N-terminal domain of Ryr2 
(Lehnart et al., 2005; Marx et al., 2000; Timerman et al., 1994; Wehrens et al., 2004a). 
FKBP12.6 is a 12.6 kDa polypeptide that binds to Ryr2 and stabilizes the closed state of the 
channel. It binds to each Ryr2 subunit separately. On the contrary, PP1 and PP2A and PKA bind 
to Ryr2 via their specific adaptor muscle A kinase-anchoring protein (mAKAP) (Dodge-Kafka et 





zipper motifs to facilitate binding of mAKAP. There are three well-studied phosphorylation sites 
in Ryr2. PKA mainly phosphorylates Ryr2 at serine position 2808 and 2030 (Xiao et al., 2006). 
In addition, PDE4D3 and phosphatases are targeted to the Ryr2 signaling complex and locally 
regulate cyclic adenosine monophosphate (cAMP) levels and PKA activity, respectively 
(Lehnart et al., 2005). CaMKII phosphorylates Ryr2 at serine 2814 (Wehrens et al., 2004a). The 
phosphorylation of Ryr2 regulates the channel, without directly opening or closing the channel, 
but modifying the sensitivity of the channel to its physiological ligand Ca2+.  
Since 2001, molecular genetic studies have identified mutations in the gene encoding the cardiac 
RYR2 (Priori et al., 2001) in CPVT patients. These studies have led to the intensification of 
efforts for elucidating the arrhythmogenic mechanisms underlying the disease. However, due to 
the protein size and complexity,  it is challenging to investigate the topology of mutations.  
More than 150 RYR2 mutations for CPVT have been identified until now. The overwhelming 
majority (more than 76%) of RYR2 mutations is classified in clusters in four distinct regions: 
domain a (residues 44-466), b (residues 2246-2534), c (residues 3778-4201), and d (residues 
4497-4959) (Figure 3). These regions are highly conserved in RYR2 across species (Priori and 
Chen, 2011). Most mutations identified in RYR2 are single nucleotide replacements (also called 
“point mutations”) leading to an amino acid substitution, which is different from the other 
channelopathies where mutations such as truncations, deletions, and insertions are more common. 
Only a small number of mutations (less than 24%) are positioned in regions outside the 







Figure 3. Cartoon (top) and schematic representation (bottom) of the RYR2 protein. Clusters with 
frequent mutations are depicted with their location along the RYR2 amino acid sequence. Percentage of 
known (published) mutation for each cluster is also reported (bottom). Mutations outside the canonical 
clusters are depicted as dots (top). Each dot represents a unique mutation (Priori and Chen, 2011). With 
permission from Wolters Kluwer Health, Inc. 
 
The structure of this complex protein becomes more clearly thanks to the technology 
improvements of cryo-electron microscopy. In 2016, the group of Yan has uncovered the 
structure basis for the gating mechanism of Ryr2 from the porcine heart (Peng et al., 2016). 
Several domains based on the structure are proposed, including N-terminal domain, SPRY1, 
phosphorylation site 1, SPRY2, SPRY3, handle domain 1, phosphorylation site 2, handle domain 
2, helical domain, central domain, and channel domain. It is obvious that there are tight overlays 
for domain a (residues 44-466), b (residues 2246-2534), c (residues 3778-4201), and d (residues 
4497-4959) to N-terminal domain (residues 1-642), helical domain 1 (residues 2111-2679), 








Figure 4.  The cryo-electron microscopy structure of Ryr2 from the porcine heart in a closed stage. 
Domain organization of a porcine Ryr2 protomer (A). The domain boundaries are indicated, with the 
reliably assigned boundaries labeled red. The tetrameric closed state structure of porcine Ryr2 is domain-
colored with the same scheme (B) (Peng et al., 2016). With permission from American Association for 
the Advancement of Science. 
 
1.1.4 Pathophysiological mechanisms of CPVT triggered by RYR2 mutations 
 
It is believed that an interaction of the individual domains is essential for the channel function 
(Medeiros-Domingo et al., 2009). Nowadays, four hypotheses or mechanisms were proposed to 
explain the CPVT pathophysiology.  
 
(1) RYR2 mutations cause Ca2+ leak at lower luminal Ca2+ concentration 
This mechanism was first described by the Chen’s group in 2004 (Jiang et al., 2004). In normal 
cardiomyocytes (CMs), an action potential (AP) activates the voltage-dependent L-type Ca2+ 
channel, leading to a small Ca2+ current influx. This Ca2+ entry induces the RYR2 channel open, 
resulting in SR Ca2+ release and muscle contraction. This mechanism is called calcium-induced 
calcium release (CICR). The free SR Ca2+ level is predominantly determined by CASQ2. RYR2 





When CPVT CMs are stimulated by catecholamine or stress, an abrupt increase of free SR Ca2+ 
occurs. In CPVT, the threshold for SOICR is reduced due to the RYR2 mutations. The resting 
level of free SR Ca2+ in CPVT might have adapted to a reduced level due to the existence of SR 
autoregulation. Under the stimulation condition, the free Ca2+ level reaches the SOICR threshold, 
SOICR occurs, leading to a large SR Ca2+ spillover, which in turn can generate delayed 
afterdepolarizations (DADs) and triggered arrhythmia (TA) (Jiang et al., 2004) (Figure 5). 
 
 
Figure 5. A proposed mechanism for CPVT associated with RYR2 mutations. Schmatic 
presentation of the relationship between the threshold for SOICR and the free Ca2+ level in normal 
(A) and CPVT SR (B) in the resting and stimulated states. The threshold for SOICR, which is primarily 
determined by RYR2, is depicted by a red bar. The threshold for SOICR is reduced in CPVT due to the 
RYR2 mutations. Blue area represents the free SR Ca2+ level. The resting level of free SR Ca2+ in 
CPVT might have adapted to a reduced level due to the existence of SR autoregulation. An abrupt 
increase of free SR Ca2+ is depicted by the yellow area when the cell stimulated by catecholamines or 
stresses. When the free SR Ca2+ level reaches the SOICR threshold, SOICR occurs, leading to a large 
SR Ca2+ spillover, which in turn can generate DADs and TAs (Jiang et al., 2004). Copyright (2004) 






(2) RYR2 mutations cause the disruption of domain-domain interaction 
This mechanism was first proposed by the Matsuzaki’s group in 2011 (Suetomi et al., 2011). In 
the normal RYR2, the N-terminal domain and the helical domain 1 (Figure 6) interact with each 
other to function as a regulatory switch for RYR2 channel gating. This interaction forms with a 
tight “zipping” of the two interacting domains, which serves to stabilize the channel. A mutation 
in either domain weakens the domain-domain interaction, leading to an unzipping of the two 
interacting domains, which causes the leakiness of RYR2 channel (Dobrev et al., 2012; 
Kobayashi et al., 2009; Suetomi et al., 2011) (Figure 6). This hypothesis is supported by using 
cells co-transfected with single yellow fluorescent protein (YFP) (RYR2S437-YFP) and single 
cyan fluorescent protein (CFP) (RYR2S2367-CFP) labeled RYR2, indicating that the interaction 
between the RYR2S437 and RYR2S2367 spots is an inter-subunit interaction (Liu et al., 2010). 
 
Figure 6. RYR2 mutation causes the disruption of domain-domain interaction. Normal 
RYR2 function also requires proper interaction between the amino-terminal domain (blue) and a 
central domain (orange), stabilizes the channel in its closed state, thus preventing diastolic Ca2+ leak 
from the SR. The RYR2 mutations in CPVT caused amino-terminal domain and central domain 
unzipping, destabilizing the closed state of RYR2, resulting in diastolic Ca2+ leak from the SR that may 
activate the Na+/Ca2+ exchanger to produce DADs and/or TAs (Dobrev et al., 2012). With permisssion 
from Nature publishing Group. 
 
(3) RYR2 mutations cause the disruption of FKBP12.6 binding 
Andrew Marks suggests that FKBP12.6 acts as a “stabilizer” that maintains the RYR2 channel 





demonstrate that FKBP12.6 binding to RyR2 R2474S is significantly reduced under adrenergic 
stimulation. It has been hypothesized that some RYR2 mutants present a reduced binding affinity 
to FKBP12.6 under basal conditions and this defect is further amplified by PKA phosphorylation 
of RYR2, which leads abnormal Ca2+ leak from the SR during diastole (Liu et al., 2009; Marx et 
al., 2000) (Figure 7).   
 
       A                                                  B 
 
Figure 7. RYR2 mutation causes the disruption of FKBP12.6 binding. (A) The wild-type RYR2 is 
closed in diastole while during systole it opens. (B) The mutant RYR2 opens during systole and is 
leaky during diastole. FKBP12.6 (yellow ovals) acts as a “stabilizer” that preserves the RYR2 channel 
closed during diastole (Liu et al., 2009). With permission from Elsevier. 
 
(4) RYR2 mutations cause loss-of-function of the RYR2 channel  
The three mechanisms mentioned above for CPVT arrhythmogenesis require RYR2 affected by 
gain-of-function mutations. Recently, Zhao et al. (Zhao et al., 2015) reported a loss-of-function 
mutation of RYR2 that was originally described in humans, and elucidated novel mechanisms by 





stimulated ventricular myocytes, the RYR2 loss-of-function mutation decreases the peak of Ca2+ 
release during systole, gradually overloading the SR with Ca2+. The resultant Ca2+ overload then 
randomly causes bursts of prolonged Ca2+ release, inducing electrogenic Na+/Ca2+ exchanger 
activity and triggering EADs in systole (Figure 8). 
 
Figure 8. The RYR2A4860G mutation causes loss-of-function. In a single RYR2A4860G CM containing 
functionally divergent RYR2 channels (WT shown in violet, mutation shown in bronze), a normal L-
type calcium current first elicits a [Ca2+]i transient. The lower amplitude of the [Ca2+]i transient leaves a 
residual amount of Ca2+ inside the SR, which gradually builds up. This process is repeated N times 
until the SR Ca2+ load reaches a threshold that is sufficient to activate hyporesponsive RYR2 channels, 
which then release Ca2+ and further activate neighboring RYR2 channels, enhancing calcium-induced 
calcium release. The activation of hyporesponsive RYR2 channels immediately after an initial burst of 
peak Ca2+ release generates a pedestal phase of Ca2+ release that supercharges the sarcolemmal 
Na+/Ca2+ exchanger, generating an EAD (Zhao et al., 2015). Copyright (2015) National Academy of 
Science. 
 
1.1.5 Current therapies for CPVT 
 
Patients with CPVT are generally recommended to avoid overwhelming emotions, strenuous 
exercise, and competitive sports. First-line therapy for CPVT is β-blockers combined with 
exercise restriction. Nadolol, a long-acting, non-selective β-blocker, is preferred for prophylactic 
treatment of CPVT. Propranolol, another non-selective β-blocker, is also an effective medication. 
The third generation of β-blocker carvedilol, which is a non-selective β-blocker and α1-blocker, 
is reported to inhibit the arrhythmic events in CPVT. However, β-blockers cannot completely 





dosages or a poor drug compliance or polymorphisms, the efficacies of β-blocker treatment are 
apparent discrepancy among various studies (Leenhardt et al., 2012).  
Flecainide acetate is a class Ic antiarrhythmic agent used to prevent and treat tachyarrhythmias. 
The efficacy of flecainide is first observed in a CPVT CASQ2 knockout mouse model, showing 
a reduction of ventricular arrhythmia both in vitro and in vivo through Ryr2 blockage (Watanabe 
et al., 2009). Routine use of flecainide monotherapy is not recommended because the evidence is 
scarce, despite the side effects of flecainide are mild in contrast to β-blockers (Lieve et al., 2016). 
The proposed underlying mechanism of the action of flecainide is controversial. Apart from the 
known sodium channel blocking effect, flecainide has an additional uncertain direct blocking 
effect on the RYR2 channel (Bannister et al., 2015).  
Implantable cardioverter-defibrillators (ICDs) are recommended for patients with CPVT who 
experience cardiac arrest, recurrent syncope or ventricular tachycardia (VT) despite β-blockers 
and flecainide medical therapy. Furthermore, in those individuals for whom the highest tolerated 
dose of β-blockers fails to adequately control arrhythmias (Priori, 2002), an ICD can be the 
primary prevention of cardiac arrest/sudden death. However, there are significant drawbacks to 
ICD therapy, because several case reports have shown the potential proarrhythmic properties of 
the ICD. An ICD shock may cause a subsequent catecholamine release, which in turn can trigger 
more ventricular arrhythmias and lead to a ventricular arrhythmic storm (Lieve et al., 2016) 
Left cardiac sympathetic denervation is used to treat angina pectoris, long-QT syndrome and 
highly lethal acute myocardial infarction (van der Werf et al., 2012b). This surgery may be 
considered for those CPVT patients who have several appropriate ICD shocks while on β-
blocking agents and for those who are intolerant or have contraindication to β-blocker therapy 
(Priori et al., 2013). However, left cardiac sympathetic denervation have many side effects, 
including palpebral ptosis, elevation of the left hemidiaphragm, and lack of sweating from the 
left arm and face. Pharmacologic therapy should be always optimized prior to considering this 
therapy, also due to recurrences of cardiac arrhythmic events that have been reported in those 
with this therapy (Napolitano. et al., 2014).  
 






1.2.1 Human induced pluripotent stem cells 
 
Stem cells are characterized by the ability to self-renew and to generate differentiated functional 
cell types (Jaenisch and Young, 2008). Since pluripotent stem cells have the greatest 
developmental and therapeutic potential, they have been intensely investigated for more than six 
decades. Embryonic stem cells (ESCs) were first derived from the inner cell mass of mouse 
blastocysts (Evans and Kaufman, 1981) and subsequently from human embryos (Thomson et al., 
1998).  
Obtaining and isolation of human ESCs means destruction of the embryo, which causes critical 
political and ethical problems. Therefore, the possibility of reprogramming differentiated somatic 
cells and setting them back in a pluripotent state provides a powerful tool for developmental and 
clinical research without ethical problems. 
In 2006, Takahashi and Yamanaka achieved a significant breakthrough in reprogramming 
somatic cells back to an ESC-like state in mouse model (Takahashi and Yamanaka, 2006). They 
successfully reprogrammed mouse embryonic fibroblasts (MEFs) and adult fibroblasts to 
pluripotent ESC-like cells, so-called induced pluripotent stem cells (iPSCs), after viral-mediated 
transduction of the four transcription factors OCT3/4 (octamer-binding transcription factor 3/4), 
SOX2 (sex determining region Y-box 2), c-MYC, and KLF4 (Krüppel-like factor 4). 
Subsequently, human iPSCs were generated from fibroblasts using the same combination of 
transcription factors (Takahashi et al., 2007) using retroviruses or using different combinations 
like OCT4 (Octamer-binding transcription factor 4), SOX2, NANOG and LIN28 (Yu et al., 2007) 
using lentiviral vectors.  
Retrovirus and lentivirus are potentially harmful genome-integrating viruses. This leads to 
insertion mutations, which for instance could lead to diverse mutations or even cell death if an 
essential gene is affected. Regarding the transgenic integration and genomic instability, non-viral 
and non-integrating methods have been explored. There are examples of integration-free vector 
systems: adenoviruses (Stadtfeld et al., 2008), Sendai viruses (Fusaki et al., 2009),  and plasmids 
(Okita et al., 2011) as well as proteins (Zhou et al., 2009) or even chemicals (Hou et al., 2013). 
Besides the reprogramming methods, different sources or cell types have been applied, including 





pulp cells (Tamaoki et al., 2010), keratinocytes (Streckfuss-Bomeke et al., 2013) and bone 
marrow cells (Streckfuss-Bomeke et al., 2013). 
Human iPSCs (hiPSCs) resemble human ESCs in defining features like morphology, expression 
of pluripotency markers, self-renewal, and teratoma formation. However, hiPSCs might retain 
epigenetic memory of the somatic cells of origin (Vaskova et al., 2013), making it more difficult 
to differentiate to specific cell types. Long-term culture of iPSCs diminish the epigenetic 
memory of differentially methylated regions, implying that iPSCs lose the characteristics 
inherited from the parent cells and adapt to very closely resemble ESCs over time (Nishino et al., 
2011).  
 
1.2.2 Direct differentiation of hiPSCs into CMs 
 
In early studies using pluripotent stem cells as a source for cardiac cells, the embryoid body (EB) 
method was applied, but resulting in very low CM differentiation efficiency. Here, the 
pluripotent cells are cultivated in suspension in small aggregates, which results in spontaneous 
but not directed differentiation into cells of all three germ layers (Amit and Itskovitz-Eldor, 
2002). 
The differentiation into mesodermal cells is mainly regulated by transforming growth factor type 
β (TGFβ), bone morphogenic protein, fibroblast growth factor (FGF) and WNT (derived from 
the combination of both names wingless and int). The canonical WNT pathway is crucial for 
cardiac development. Recently, it is reported that modulation of canonical WNT/β-catenin 
signaling under fully defined conditions in iPSCs is sufficient for directed differentiation into 
CMs (Lian et al., 2012). The iPSCs were first differentiated into mesendoderm cell by the 
inhibition of glycogen synthase kinase 3 and then into cardiac mesoderm by the inhibition of 
Wnt signaling pathways. The protocols Lian et al. developed are sufficient to yield a high 
virtually purity (80-98%) of functional CMs in 14 days from multiple hiPSC lines without cell 
sorting or selection (Lian et al., 2013). Furthermore, by changing the B27TM supplemented basal 
medium RPMI 1640 to a chemically defined medium consisting of just three components: the 
basal medium RPMI 1640, L-ascorbic acid 2-phosphate and rice-derived albumin (recombinant 





reported that this protocol produced contractile sheets of up to 95% cardiac troponin T-positive 
CMs at a yield of up to 100 CMs for every input pluripotent cell and was effective in 11 hiPSC 
lines tested (Burridge et al., 2014). 
 
1.2.3 Disease modeling for CPVT 
 
Ebert et al. firstly conducted their research on spinal muscular atrophy using hiPSCs to model 
genetically inherited disease to study the specific pathology characters (Ebert et al., 2009). In the 
past 10 years, an increasing number of studies were reported, in which patient-specific hiPSCs 
were used for modelling cardiovascular diseases, including  Long QT syndrome type 1 (Egashira 
et al., 2012; Moretti  et al., 2010; Sogo et al., 2016), type 2 (Itzhaki et al., 2011; Lahti et al., 
2012; Matsa et al., 2011), type 3 (Malan et al., 2011; Terrenoire et al., 2013), familial 
hypertrophic cardiomyopathy (HCM) (Lan et al., 2013), Timothy syndrome (Yazawa et al., 
2011), CPVT (Di Pasquale et al., 2013; Fatima et al., 2011b; Itzhaki et al., 2012; Jung et al., 
2012; Kujala et al., 2012; Novak et al., 2015; Novak et al., 2012; Penttinen et al., 2015; 
Preininger et al., 2016; Zhang et al., 2013a), and dilated cardiomyopathy (DCM) (Gramlich et al., 
2015; Sun et al., 2012). The generation of disease-specific CMs differentiated from hiPSCs 
(hiPSC-CMs) provides a tool for the identification of the pathophysiological and molecular 
mechanisms in cardiac channelopathies. Despite iPSC-CMs are still immature in comparison to 
adult myocytes, this technology overcomes the impossibility of harvesting adult human CMs 
from patients and expanding them in culture.  
Dozens of literature focused on CPVT disease modeling have been published nowadays. Two 
hiPSC models with two mutations in N-terminal domain of RYR2 are reported, one is S406L 
(Jung et al., 2012) and the other is R420Q (Novak et al., 2015). The authors prove the defective 
inter-domain interactions within the RYR2 channel as the pathomechanism of the S406L 
mutation by using dantrolene to restore normal Ca2+ spark properties and to rescue the 
arrhythmogenic phenotype (Jung et al., 2012). By using RYR2R420Q as a representative for 
CPVT1 and CASQ2D307H mutation for CPVT2, the authors compared the similarities/differences 
in ultrastructure, calcium handling and other aspects between RYR2 versus CASQ2 mutations 





RYR2 mutations E2311D (Di Pasquale et al., 2013) and F2483I (Fatima et al., 2011a; Zhang et 
al., 2013a), which located in helical domain 1 of RYR2 (Figure 4). An antiarrhythmic drug KN-
93 drastically reduces the presence of DADs and rescues the arrhythmic phenotype induced by 
ISO in CPVTE2311D-CMs through CaMKII inhibition (Di Pasquale et al., 2013). One group 
reports that RYR2F2483I mutant hiPSC-CMs have aberrant unitary Ca2+-signaling, smaller Ca2+ 
stores, higher CICR gain (Zhang et al., 2013a). The other group reports that RYR2F2483I hiPSC-
CMs exhibit DADs and higher amplitudes and longer durations of spontaneous Ca2+ release 
events at basal state (Fatima et al., 2011a). Itzhaki et al. showed that flecainide could eliminate 
all afterdepolarizations induced by ISO in hiPSC-CMs with the RYR2M4109R mutation (located in 
central domain). Importantly, the threshold for SOICR is significantly reduced in the 
CPVTM4109R CMs (Itzhaki et al., 2012). In 2016, Preininger et al.  provide new evidence that 
iPSC-CMs can recapitulate patient-specific drug responses to β-blockers, by testing flecainide 
and β-blocker on the iPSC-CMs harboring novel mutation RYR2L3741P. The mutation L3741P 
locates in the central domain of RYR2 based on the discovery of latest structure (Figure 4). 
Recently, a systemic CPVT investigation is using recruited patients and iPSC-CMs to assess 
various mutations distributed in different mutation hotspots and to test the antiarrhythmic effects 
of dantrolene (Penttinen et al., 2015). Dantrolene reduces the number of premature ventricular 
complexes (PVC) on average by 74% (range 33-97%) in four patients with RYR2 mutations in 
helical domain 1 (P2328S, T2538R, and L4115F) in the cytosolic region of the RYR2 protein, 
while dantrolene has no effect in two patients with RYR2 mutations in transmembrane domain 
(V4653F) or central domain (Q4201R) (Penttinen et al., 2015). The similar results are obtained 
in iPSC-CMs with RYR2 mutations in the helical domain 1 (P2328S, T2538R, and L4115F), 
dantrolene suppress the Ca2+ cycling abnormalities in 80% (range 65-97%) of cells while the 
other mutations only in 23 or 32% of iPSC-CMs with mutations transmembrane domain 
(V4653F) or central domain (Q4201R)  (Penttinen et al., 2015). 
 
1.3 cAMP dynamic in cardiomyocytes 
 
cAMP is a very important second messenger in many biology processes. In the mammalian heart, 





chronotropic, inotropic and lusitropic effects (Boularan and Gales, 2015). Catecholamine-
induced activation of β-ARs via adrenaline or noradrenaline leads to the regulation of 
intracellular cAMP production in CMs. Recent cardiovascular research shows that three different 
types of β-ARs are expressed in mammalian hearts: β1-, β2- and β3-ARs (Imbrogno et al., 2015). 
The β1-AR represents 70-80% of total β-ARs in the non-aged heart.  
The PKA phosphorylation of several downstream targets, which include L-type Ca2+ channel 
(LTCC), phospholamban, RYR2, and troponin I, results in enhanced calcium current, increased 
Ca2+ reuptake mediated by sarco/endoplasmic reticulum Ca2+-ATPase 2a, increased Ca2+ release 
from the SR, and altered Ca2+ sensitivity of the myofilaments to increase cardiac performance 
and output (Bers, 2002). 
Phosphodiesterases (PDEs) play an essential role in cAMP dynamic by degrading cAMP. There 
are 11 families of distinct mammalian PDEs based on sequence homology, enzymatic properties, 
and sensitivity to inhibitors (Omori and Kotera, 2007; Zaccolo, 2006). However, at least six 
different PDE families are expressed in animal hearts, including PDE1-5 and PDE8 (Miller and 
Yan, 2010; Xiang, 2011).  
 
1.3.1 Altered cAMP dynamic in cardiovascular disease 
 
PDE2 and PDE3 have dual substrate specificity and can hydrolyze both cAMP and 3'-5'-cyclic 
guanosine monophosphate (cGMP), whereas PDE4 hydrolyses cAMP exclusively. The role of 
PDE2 in cardiac physiology in vivo has not been well characterized, although several previous 
reports focus on the LTCC effected by PDE2 hydrolization via NO/cGMP singling pathway 
(Dittrich et al., 2001; Mongillo et al., 2006; Rivet-Bastide et al., 1997). It is reported that PDE2 
activity was up-regulated in response to pressure overload of rat ventricles under pathological 
conditions, but the absence of significant changes in PDE2A mRNA levels indicated that the 
PDE2 activity was post-transcriptionally up-regulated (Yanaka et al., 2003). In failing human 
hearts, an increased amount of AKAP-bound PDE2 may prevent PDE2 from hydrolyzing cyclic 
nucleotides, and contribute to the pathology of heart failure (Aye et al., 2012). Recently, Mehel 
et al. reported that PDE2 was up-regulated in human failing hearts and desensitized against acute 





(Zoccarato et al., 2015). Amrinone, milrinone and enoximone, which are known as PDE3 
inhibitors, have been used to treat congestive heart failure (Baim  et al., 1983). Several clinical 
trials have revealed that long-term treatment with PDE3 inhibitors in severe chronic heart failure 
patients is associated with increased mortality and mobility due to arrhythmias and sudden 
cardiac death (Packer, 1989; Packer  et al., 1991). Loss of cardiac efficacy of PDE3 inhibitors 
has been proposed to associate with disease-related reduction of PDE3 function in several early 
studies by using left ventricular muscles from patients with various stages of heart failure. 
Moreover, Chen et al. have demonstrated that the overall PDE3 activity and PDE3A protein 
levels were significantly reduced in left ventricular myocardial samples from patients with end-
stage DCM and ischemic heart disease (Ding et al., 2005; Yan et al., 2007). The decreasing of 
PDE3 activity and PDE3 protein levels in left ventricular endocardium has also been observed in 
pacing-induced failing canine hearts (Sato et al., 1999). Two similar researches demonstrate a 50% 
to 59% reduction of PDE3A/GAPDH ratios in both left and right ventricular of pacing-induced 
canine heart failure model (Smith et al., 1998; Smith et al., 1997). Consistent with PDE3A 
mRNA levels, PDE3A protein was decreased in the canine failing hearts in those two studies. 
Interestingly, Wu et al. reported that PDE2A and 3A were upregulated in CMs in an iPSC model 
of DCM via epigenetic regulation (Wu et al., 2015). 
PDE4A, 4B, and 4D are expressed in the heart (Abi-Gerges et al., 2009; Galindo-Tovar and 
Kaumann, 2008; Lehnart et al., 2005; Leroy et al., 2011; Mika et al., 2014; Molina et al., 2012; 
Takahashi et al., 2002; Xiang et al., 2005), which are highly specific for cAMP. PDE activity 
assays reveal that PDE4 is responsible for approximately 10% of total cAMP hydrolytic activity 
in human, approximately 30% in mouse, and 50–60% in rat (Richter et al., 2011). Studies in 
murine heart with genetic depletion of PDE4B and PDE4D reveal that these subtypes are 
important for normal regulation of CICR in CMs, and depletion of any of them can cause 
arrhythmia upon transient β-adrenergic stimulation (Leroy et al., 2011).  
Moreover, the PDE4D3 isoform is reported to interact with the RYR2 complex via mAKAP 
(Dodge-Kafka et al., 2005; Dodge et al., 2001) and acts as a key regulator of PKA-mediated 
RYR2 phosphorylation (Lehnart et al., 2005). Both knockout and inhibition of PDE4D in the 
complex resulted in RYR2 hyperphosphorylation and SR Ca2+ leakage, and finally 
catecholaminergic arrhythmogenesis (Lehnart et al., 2005). This is also confirmed by PDE4D 






1.3.2 Fluorescence resonance energy transfer 
 
Fluorescent resonance energy transfer (FRET) describes the interaction between a donor 
fluorophore, initially in its excited state, which may transfer energy to an acceptor fluorophore 
through non-radiative energy transfer way (Förster, 1948).  
These electrons are lifted from the unexcited single state S0 to its excited state S1 after 
absorption of photon energy. Due to the emission spectrum of the donor fluorophore overlapping 
with the excitation spectrum of the acceptor fluorophore, the acceptor fluorophore is excited to 
S1 with a close proximity of less than 10 nm (Wu and Brand, 1994). The acceptor electrons are 
lifted from S0 to the S1 state after absorbing the energy emitted by the acceptor fluorophore. 
Again, fluorescence is emitted as the acceptor electrons return to the S0 state (Figure 9). 
A                                                            B 
                
Figure 9. FRET mechanism (CFP-YFP FRET pair). (A) Schematic illumination of the Jablonski-
diagram: after absorption of photon energy, the donor electrons are transitioned from a ground state 
(S0) to an excited state (S1). The donor fluorophore can partly transfer its energy from its lowest S1 
level to the electrons of an acceptor fluorophore with a lower energetic excitation spectrum 
(fluorophore distance must be ≤10 nm). Acceptor electrons are lifted from their S0 to the S1 level and 
fluorescence (hv) is emitted when the acceptor electrons “fall back” into their S0 level. (B) Shown is 
the needed grey colored spectral overlap, here CFP and YFP as an example. The emission of the donor 
fluorophore (CFP) and the absorption spectrum of the acceptor YFP overlaps to allow fluorescence 






1.3.3 FRET-based cAMP biosensors 
 
Cyclic AMP content in all cell types or tissues can be traditionally measured by standard 
antibody-based techniques such as radioimmunoassays and enzyme-linked immunoassays 
(Brooker et al., 1979; Williams, 2004). These methods allow quantification of total cAMP 
content (free cytosolic cAMP plus cAMP bound to various proteins) after lysis or mechanical 
disruption of the tissue.  
In the past decades, the FRET technique has gained great popularity in the study of biochemical 
events and protein-protein interactions in life science, especially in cAMP dynamic. Traditional 
methods have no spatial resolution and do not allow measurements of physiologically relevant, 
free cAMP concentrations in intact living cells or in various subcellular locations within one cell. 
In 1991, Adams et al. created the pioneer FRET-based cAMP sensor, named FlCRhR. This 
probe consists of a PKA holoenzyme with two fluorescent dyes chemically fused to the R- and 
C-subunits of PKA and needs to be microinjected into living cells to monitor PKA dissociation 
upon elevation of intracellular cAMP and its re-association when cAMP is decreased.  
Up to now, a series of genetically encoded cAMP biosensors have been generated, which are 
easily introduced into cells by transfection of the DNA construct to monitor cAMP with high 
spatiotemporal resolution (DiPilato et al., 2004; Nikolaev et al., 2004; Nikolaev et al., 2006; 
Ponsioen et al., 2004; Zaccolo and Pozzan, 2002). Highly notable is a transgenic mouse model 
with ubiquitous expression of the cytosolic cAMP indicator Epac1-cAMP-sensor (Epac1-camps) 
(Calebiro et al., 2009). The short name of exchange factor directly activated by cAMP 1 is 
EPAC1, which is widely distributed in CMs. Epac1-camps contains a cAMP binding domain 
derived from Epac1, sandwiched between CFP and YFP as a FRET pair (Figure 10). In CMs, 
transient expression of such biosensors is commonly achieved via transfection of neonatal CMs 
or adenoviral gene transfer in adult CMs (Kirshenbaum et al., 1993). Expression of a functional 
FRET biosensor via adenovirus in adult myocytes requires at least 40-48 hours during which 
dedifferentiation and remodeling of normal cell physiology are likely to occur (Horackova and 







Figure 10. Principle of the Epac1-cAMP-sensor (Epac1-camps). Epac1-camps is based on a single 
cAMP binding domain from Epac1 fused between CFP and YFP. At low cAMP levels, the donor 
(CFP) and acceptor (YFP) are nearby and FRET occurs. Binding of cAMP to the cAMP binding 
domain induces a conformational change and a concomitant decrease in FRET. Excitation of CFP is at 
436 nm, CFP and YFP emission are collected at 480 and 535 nm, respectively (Nikolaev and Lohse, 
2006). With permission from American Physiological Society. 
 
In CMs, several cAMP microdomains have been proposed, which are located, for example, 
around Ca2+ handling proteins such as LTCCs, RYR2 and sarco/endoplasmic reticulum Ca2+-
ATPase 2a, since cAMP is not uniformly distributed within the cell but is rather organized in 
subcellular compartments (Fischmeister et al., 2006).  
 
1.4 Aims of this Ph.D. thesis 
 
The hypotheses of this project included: the CPVT phenotypes and pathophysiological 
mechanisms are mutation-specific; antiarrhythmic effects of drugs are mutation-specific. To test 
the hypotheses, the aims of this project were to establish in vitro disease models using iPSCs 
from six patients with CPVT carrying the different RYR2 heterozygous missense mutations 
(R420W, A2254V, E4076K, and H4742Y) in the domain a, b, c and d, to investigate the 





pathophysiological mechanism of the disease and to explore drug therapies. The scientific and 
technological main objectives of the project included: 
 
(1) Generation and characterization of iPSC lines from two patients with CPVT carrying the 
mutation RYR2R420W and iPSC lines from one patient with CPVT carrying the mutation 
RYR2H4742Y, as well as differentiation and characterization of iPSC-CMs. 
(2) Electrophysiological phenotype characterization of CPVT-iPSC-CMs compared to CMs 
derived from iPSCs from healthy donors (Ctrl-iPSC-CMs). 
(3) Test the efficacy of four antiarrhythmic drugs (flecainide, dantrolene, rycal1, rycal2) on 
CPVT-iPSC-CMs. 
(4) Explore cAMP dynamic in CPVT-iPSC-CMs compared to Ctrl-iPSC-CMs. 










Mouse embryonic fibroblasts (MEFs): isolated from 15- to 17-day-old embryos of Naval 
Medical Research Institute mice (Central Animal Facility, University Medical Center Göttingen). 
Human induced pluripotent stem cells (hiPSCs):  All hiPSC lines used in this study were 
generated in the laboratory of Prof. Guan and are listed in Table 2. The iPSC lines of WT-D2, 
iBM76.1 and iBM76.3 were generated previously from healthy donors using the lentivirus 
system containing the STEMCCA cassette (Streckfuss-Bomeke et al., 2013). The iPSC lines 
from CPVT patients b1, c1 and c2 were generated using both the STEMCCA lentivirus system 
and Sendai virus system. In this thesis work, the generation and characterization of the cell lines 
of CPVTa2, CPVTa3, and CPVTd1 patients were performed by using the Sendai virus system 
(Materials and methods 2.1.3). The usage of human tissue was approved by the ethics committee 
of Universitätsmedizin Göttingen (Az. 21/1/11). 






Virus used iPSC lines per 
patient 




b A2254V CPVTb1 STEMCCA iCPVTb1.1-2 
Sendai isCPVTb1.2-3 
c E4076K CPVTc1 
CPVTc2 
STEMCCA iCPVTc1.1, 6 
iCPVTc2.1-2 
Sendai isCPVTc1.1, 7 
isCPVTc2.2, 4 
d H4742Y CPVTd1 Sendai isCPVTd1.4, 10, 11 
Control 1 No BM STEMCCA   iBM76.1, 3 










All oligonucleotides used for polymerase chain reaction (PCR) were purchased from Eurofins 
MWG Operon. The sequences are listed in alphabetical order (Table 3) together with the 
amplified fragment length (F), annealing temperature (TA), and number of cycles (C). 
Table 3. Oligonucleotides used for DNA sequencing and PCR analyses 
Gene Sequence F [bp] TA [°C] C 
AFP for: 5´-ACT CCA GTA AAC CCT GGT GTT G-3´ 
rev: 5´-GAA ATC TGC AAT GAC AGC CTC A-3´ 
255 60 33 
ALB for: 5´-CCT TTG GCA CAA TGA AGT GGG TAA CC-
3´ 
rev: 5´-CAG CAG TCA GCC ATT TCA CCA TAG G-3´ 
284 62 35 
α-MHC for: 5´-GTC ATT GCT GAA ACC GAG AAT G-3´ 
rev: 5´-GCA AAG TAC TGG ATG ACA CGC T-3´ 
413 60 35 
cTNT for: 5´-GAC AGA GCG GAA AAG TGG GA-3´ 
rev: 5´-TGA AGG AGG CCA GGC TCT AT-3´ 




rev: 5´- CGTTTCTGCTGACTTACCAAACAG-3´ 





370 55 30 
FOXD3 for: 5´-GTG AAG CCG CCT TAC TCG TAC-3´ 
rev: 5´-CCG AAG CTC TGC ATC ATG AG-3´ 
353 61 38 
GAPDH for: 5´-AGA GGC AGG GAT GAT GTT CT-3´ 
rev: 5´-TCT GCT GAT GCC CCC ATG TT-3´ 
265 55 34 
GDF3 for: 5´-TTC GCT TTC TCC CAG ACC AAG GTT TC-3´ 
rev: 5´-TAC ATC CAG CAG GTT GAA GTG AAC 
AGC ACC-3´ 
331 54 32 
LIN28 for: 5´-AGT AAG CTG CAC ATG GAA GG-3´ 
rev: 5´-ATT GTG GCT CAA TTC TGT GC-3´ 
410 52 36 
NANOG for: 5´-AGT CCC AAA GGC AAA CAA CCC ACT TC-
3´ 
164 64 36 




rev: 5´-ATC TGC TGG AGG CTG AGG TAT TTC TGT 
CTC-3´ 
SYP for: 5´-GCC TGT CTC CTT GAA CAC GAA C-3´ 
rev: 5´-TAC CGA GAG AAC AAC AAA GGG C-3´ 
288 56 35 
TH for: 5´-GCG GTT CAT TGG GCG CAG G-3´ 
rev: 5´-CAA ACA CCT TCA CAG CTC G-3´ 
215 60 34 
AFP: alpha-1-fetoprotein, ALB: albumin, α-MHC: myosin heavy chain (alpha), cTNT: cardiac 
troponin T, RYR2; Ryanodine receptor 2, FOXD3: forkhead box D3, GAPDH: glyceraldehyde-
3-phosphate dehydrogenase, GDF3: growth differentiation factor 3, TH: tyrosine hydroxylase 
 
2.1.3 Sendai virus system used for cell reprogramming  
 
Sendai virus (called Hemagglutinating Virus of Japan) is a respiratory virus of mouse and rat, 
and is classified as mouse parainfluenza virus type I belonging to the Paramyxoviridae family. 
Sendai virus is an enveloped virus of 150–250 nm in diameter, whose genome is a single-
stranded negative-sense RNA (15,384 bases). The Sendai virus system CytoTune®-iPS 
Reprogramming Kit was purchased from Thermo Fisher Scientific. The reprogramming vectors 
used in this study include the four Yamanaka factors OCT4, SOX2, KLF4, and c-MYC, shown to 




Table 4. Primary antibodies used for immunofluorescence 
Antigen Type Supplier Dilution 
AFP Polyclonal rabbit IgG Dako, A0008 1:100 
α-actinin mouse IgG1 Sigma-Aldrich®, 
A7811 
1:1000 
β III -tubulin mouse IgG2A Covance®, MMS-
435P 
1:2000 




Cx43 rabbit IgG Abcam®, ab11370 1:1000 
LIN28 goat IgG R&D Systems®, 1:300 





MLC2a mouse IgG2B Synaptic Systems, 
311-011 
1:500 
MLC2v rabbit IgG Protein tech® 10906-
1-AP 
1:200 
NANOG goat IgG R&D Systems®, 
AF1997 
1:200 
OCT4 goat IgG R&D Systems®, 
AF1759 
1:40 
Phalloidin Alexa Fluor® 555 Life Technologies™, 
A-12379 
1:100 
SMA mouse IgG2A Sigma-Aldrich®, 
A2547 
1:3000 
SOX2 mouse IgG2A R&D Systems®, 
MAB2018 
1:50 
SSEA4 mouse IgG Abcam®, ab16287 1:100 
TRA-1-60 mouse IgM Abcam®, ab16288 1:200 
α-actinin; alpha-actinin, β III -tubulin; Class III β-tubulin, Cx43; Connexin 43, MLC2a; 
myosin light chain 2 atrial, MLC2v; myosin light chain 2 ventricular, SMA; smooth muscle 
actin, SOX2; sex-determining region Y-Box 2, SSEA4; stage-specific embryonic antigen-4, 
TRA-1-60; tumour-related antigen-1-60 
 
Table 5. Secondary antibodies 
Antibody Supplier Dilution 
Alexa Flour 488-conjugated goat-α-
mouse IgG 
Life Technologies™, A-11001 1:200 
Cy3-conjugated donkey-α-goat IgG Jackson ImmunoResearch, 705-166-147 1:600 
Cy3-conjugated goat-α-mouse IgG + 
IgM 
Jackson ImmunoResearch, 115-165-068 1:300 
Cy3-conjugated goat-α-rabbit IgG Jackson ImmunoResearch, 111-165-003 1:800 
FITC-conjugated donkey-α-rabbit IgG Jackson ImmunoResearch, 711-095-152 1:200 
FITC-conjugated goat-α-mouse IgG Jackson ImmunoResearch, 115-096-072 1:200 
FITC-conjugated goat-α-mouse IgM Jackson ImmunoResearch, 115-095-020 1:100 
 




2.1.5 Media, solutions, and chemicals used for cell culture 
 
Table 6. Components 
Components Supplier 
AccutaseTM PAA Laboratories, #L11-007 
Albumin (human recombinant) Sigma-Aldrich®, #A0237 
B-27® serum-free supplement (50x) Life Technologies™, #17504044 
B-27® serum-free supplement (w/o insulin, 50x) Life Technologies™, #0050129SA 
β-mercaptoethanol Serva Electrophoresis, #28625 
Bovine albumin fraction V solution (BSA, 7.5%) Life Technologies™, #15260037 
CHIR99021 Merck Millipore, #361559 
Collagenase type 2 Worthington®, #LS004176 
Collagenase type 4 Worthington®, #LS004189 
Dantrolene Sigma-Aldrich®, #D9175 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich®, #D2650 
Dulbecco’s modified Eagle medium (DMEM) Life Technologies™, #11960044 
DMEM/F-12 Life Technologies™, #31331028 
Dulbecco’s phosphate buffered saline (DPBS) Life Technologies™, #14190094 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich®, #E6758 
Essential 8™ basal medium Life Technologies™, #A1516901 
Essential 8™ Supplement Life Technologies™, #A1517101 
Fetal bovine serum (FBS) Sigma-Aldrich®, #F7524 / 
Fibroblast growth factor basic (bFGF) PeproTech, #100-18B 
Flecainide Sigma-Aldrich®, #F6777 
Gelatin Sigma-Aldrich®, #48720 
Geltrex™ Life Technologies™, #A1413301 
HEPES sodium salt solution (1 M) Sigma-Aldrich®, #H3662 
Iscove’s modified Dulbecco’s medium (IMDM) Life Technologies™, #31980022 
KnockoutTM serum replacement Life Technologies™, #10828028 
L-Ascorbic Acid 2-Phosphate Sigma-Aldrich®, #A8960 
L-glutamine (200 mM) Life Technologies™, #25030024 
Mitomycin C Serva Electrophoresis, #29805.02 
Monothioglycerol (MTG) Sigma-Aldrich®, #M6145-25ML 
Non-essential amino acids (NEAA, 100x) Life Technologies™, #11140035 
Penicillin-streptomycin solution (100x) Life Technologies™, #15140-122 
Pro-survival compound Merck Millipore, #529659 
Roswell Park Memorial Institute medium 1640 
(RPMI 1640) 
Life Technologies™, #72400-021 
RPMI 1640 (w/o glucose) Life Technologies™, #11879-020 
Sodium DL-lactate solution 60% (w/w) Sigma-Aldrich®, #L4263 
Trypsin-EDTA (0.25%), phenol red Life Technologies™, #25200056 
Thiazovivin Merck Millipore™, #420220 
Versene solution (0.48 mM EDTA) Life Technologies™, # 15040066 




Wnt antagonist II (IWP2)  Merck Millipore, #681671 
 
B27 medium: add one vial B-27® serum-free supplement (50x) into RPMI 1640, and stored at 
4°C for up to 1 week 
bFGF: dissolved in 0.1% v/v BSA/DPBS to a stock solution of 10 ng/µl, aliquoted, and stored at 
-20°C 
β-mercaptoethanol (100x for cell culture): 7 µl diluted in 10 ml DPBS and sterile filtrated  
with Steriflip® filters (0.22 µm, Merck Millipore, #SCGP00525), and stored at 4°C 
BSA/DPBS (1% w/v): 1 ml of 7.5% w/v BSA added to 6.5 ml DPBS 
Cardiac differentiation medium: 250 mg Albumin (human recombinant) and 100 mg L-
ascorbic acid 2-phosphate dissolved in 500 ml RPMI 1640 with HEPES with GlutaMax and then 
filtered to sterilize (storage for up to 1 month at 4°C) 
Cardiac digestion medium (100 ml):  Cardiac differentiation medium + 20% FBS + 5-10 µM 
Pro survival compound + 1x Pen/Strep (optional) 
CHIR99021 (12 mM stock solution): 5 mg dissolved in 0.894 ml DMSO, aliquoted, and stored 
at -20°C 
Collagenase type 2: dissolved in DMEM/F-12 to a working solution of 300 U/ml, sterile 
filtrated, aliquoted and stored at -20°C 
Collagenase type 4: dissolved in DMEM/F-12 to a working solution of 200 U/ml, sterile 
filtrated, aliquoted and stored at -20°C 
EDTA (50x): 1 g EDTA dissolved in 100 ml DPBS; pH adjusted to 7.0 with 1 M NaOH; 
sterile filtrated and stored at 4°C 
EDTA (0.5 M): 14.617 g EDTA dissolved in 50 ml dH2O, pH adjusted to 8.0 with NaOH, filled 
up to 100 ml with dH2O, sterile filtrated and stored at -20°C 
EDTA dissociation solution: 500 μl EDTA (0.5 M) in 500 ml DPBS, 0.9 g NaCl, adjust the 
osmolality to 340 mOsm; sterile filtrated and stored at 4°C 
Essential 8™ medium (510 ml): 500 ml essential 8™ basal medium, 10 ml essential 8™ 





FBS: heat inactivated for 30 min at 56°C 
Feeder layer medium (100 ml): 84 ml DMEM, 15 ml FBS, 1 ml L-glutamine 
Freezing medium (100 ml): 72 ml DMEM, 20 ml FBS, 8 ml DMSO 
Gelatin stock solution (1% w/v): 10 g gelatin dissolved in 1000 ml dH2O, autoclaved, and 
stored at 4°C 
Geltrex™: 2 mg aliquoted and stored at -80°C; dissolved in 12 ml cold DMEM/F-12 before use 
hESC medium (100 ml): 78 ml DMEM/F-12, 20 ml KnockoutTM serum replacement, 1 ml 
NEAA (100x), 1 ml β-mercaptoethanol (100x), 10 ng/ml bFGF 
Iscove medium (100 ml): 79 ml IMDM, 20 ml FBS, 1 ml NEAA, 450 µM MTG (freshly 
prepared) 
IWP2 (5 mM stock solution): 10 mg dissolved in 4.28 ml DMSO and incubated at 37°C for 
10 min, aliquoted, and stored at -20°C 
Mitomycin C stock solution: dissolved in DPBS (200 µg/ml), aliquoted, and stored at -20°C 
MTG (150 mM): 13 µl MTG diluted in 1 ml IMDM and sterile filtrated with Millex®-GS filter 
(0.22 µm, Merck Millipore, #SLGS033SS), freshly prepared before use 
Pro-survival compound (5 mM stock solution): 10 mg dissolved in 6.8 ml DMSO, aliquoted, 
and stored at -20 °C 
Thiazovivin (2 mM): 10 mg dissolved in 16.06 ml DMSO, aliquoted, storage for up to 1 year at 
-20°C 
 
2.1.6 Solutions, buffers, and chemicals for molecular biology, FRET and 
electrophysiological experiments 
 
Table 7. Components for molecular biology, FRET and electrophysiological experiments 
Components Supplier 
3-isobutyl-1-methylxanthine (IBMX) AppliChem, #A0695.0001 




Acetic acid Sigma-Aldrich®, #537020 
AgarTM Serva Electrophoresis, #200201 
Alkaline phosphatase staining kit Sigma-Aldrich®, #86R-1KT 
AmpliTaq® DNA polymerase with buffer II Life Technologies™, #N808-0167 
Bay 60-7550  Santa Cruz, #SC-396772 
Cilostamide  Sigma-Aldrich®, #C7971 
DAPI (4′, 6-diamidino-2-phenylindole 
dihydrochloride) 
Sigma-Aldrich®, #D9542 
DEPC-treated water Ambion®, #AM9915G 
dNTP mix Bioline, #BIO-39029 
Ethidium bromide Roth®, #2218 
Fluoromount-G™ eBioscience, #00-4958-02 
Formalin (37%) Merck Millipore, #1039991000 
GeneRuler™ 100 bp Plus DNA Ladder Thermo Fisher Scientific, #0321 
Giemsa stain Sigma-Aldrich®, #GS500 
GoTaq® DNA polymerase Promega, #M3175 
Isoproterenol  Sigma-Aldrich®, # I6504 
Karyomax® Colcemid® solution 
(demecolcine) 
Life Technologies™, #15210-040 
Methanol Sigma-Aldrich®, #82762 
MuLV reverse transcriptase (50 U/µl) Life Technologies™, #N808-0018 
NucleoSpin® Gel and PCR Clean-up MACHEREY-NAGEL GmbH & Co. 
Paraformaldehyde (PFA) Sigma-Aldrich®, #158127 
Polybrene® Sigma-Aldrich®, #107689 
QIAquick® gel extraction kit Qiagen, #28706 
RNase inhibitor (20 U/µl) Life Technologies™, #N808-0119 
Rolipram  Sigma-Aldrich®, #R6520 
Rycal1  From collaborator 
Rycal2  From collaborator 
SV total RNA isolation system Promega, #Z3105 
SYBR® Green PCR master mix Life Technologies™, #4309155 
Triton X-100 Sigma-Aldrich®, #3051.3 
 
0.1% TritonTM x-100/DPBS: 1 ml TritonTM x-100 diluted in 9 ml DPBS, storage at 4 °C for 6 
months. 
Agar gel (1.5% or 2% w/v): 1.5 g or 2 g DNA AgarTM dissolved in 100 ml 1x TB buffer by 
boiling in a microwave, 6 µl of 10 mg/ml ethidium bromide was added to 100 ml agar gel at 
65°C for visualization of DNA under ultraviolet light. 
FRET buffer (in mM): 144 NaCl, 5.4 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, pH adjusted to 7.3 
with KOH. 




Giemsa solution (1/20 diluted in dH2O): 1 ml Giemsa stain diluted in 19 ml dH2O, used for one 
month. 
KCl solution (0.075M): 5.59125 g KCl dissolved in 1 L dH2O, used for one year. 
PFA (4% w/v): 4 g PFA dissolved in 100 ml DPBS under heated conditions, used for 1 week. 
TB buffer (5x): 108 g Tris, 55 g boric acid, filled up to 2000 ml with dH2O.  
Pipette solution for action potential recording (in mM):  
(1): 122 L-aspartic acid potassium salt, 10 NaCl, 8 KCl, 1 MgCl2, 5 Mg-ATP, 0.3 Li-GTP, 10 
HEPES; pH adjusted to 7.2 with KOH. 
(2): 60 KCl, 100 K-Gluconate, 5 Na2-Phosphocreatine, 4 Mg-ATP, 0.3 Na-GTP, 10 HEPES; pH 




2.2.1 Cell culture 
 
All cells were cultivated under humidified conditions at 37°C and 5% carbon dioxide (incubators 
from Thermo Fisher Scientific). All culture work was performed under sterile conditions using a 
laminar airflow cabinet (Thermo Fisher Scientific) to avoid microbiological contamination. 
Tissue culture dishes (35 x 10 mm, 60 x 15 mm, 100 x 20 mm) and 6-, 12-well plates were 
bought from Starlab. 
 
2.2.1.1 Cultivation and inactivation of mouse embryonic fibroblasts 
 
MEFs were isolated from 15- to 17-day-old mouse embryos and subsequently cultivated on 0.1% 
gelatin-coated culture dishes in feeder layer medium for maximal four passages. Before used for 
cultivation of hiPSCs, MEFs were treated with a final concentration of 10 µg/ml mitomycin C 
for three hours at 37°C to stop cell proliferation. MEFs were washed three times with DPBS and 
subsequently treated with 0.25% trypsin-EDTA until the adherent cells started to detach. The 




single cells were resuspended in feeder layer medium and counted with a Thoma cell counting 
chamber. A certain number of cells (e.g. 3 x 105 cells on 6-cm dishes) were then plated onto 0.1% 
gelatin-coated culture dishes. The permit number is T10/6. 
 
2.2.1.2 Generation of hiPSCs 
 
Human iPSCs were generated by transducing human fibroblasts with the CytoTune®-iPS Sendai 
Reprogramming Kit containing four Yamanaka transcription factors OCT3/4, SOX2, KLF4 and 
c-MYC. One day before transduction, human fibroblasts were plated onto 0.1% gelatin coated 
12-well plates with 0.3 x 105 cells per well. The cells were infected with the virus provided in the 
kit at a multiplicity of infection (MOI) of 0.5, 1.0 and 2.0 in freshly prepared hESC medium 
containing 1 µg/ml polybrene and 1x penicillin-streptomycin solution. On the next day, medium 
was changed with fresh hESC medium containing 1x penicillin/streptomycin solution after 
washing the cells with hESC medium twice. The medium was changed daily. On day 7, the cells 
were passaged and cultivated on inactivated MEFs. Single colonies that appeared with typical 
hESC morphology were picked mechanically using a sharpened glass pipette and were 
propagated further on MEFs. 
 
2.2.1.3 Cultivation of hiPSCs with feeder cells 
 
In some experiments, undifferentiated hiPSCs were cultivated on mitomycin C treated MEFs in 
hESC medium. The medium was changed daily, and colonies were split every 4 to 5 days. The 
cells were treated with 200 U/ml collagenase type 4 for 5 min at 37°C followed by two washing 
steps with DMEM/F-12. The cells were additionally cut into small clusters using a cell scraper 
(Sarstedt). After pipetting two to three times up and down, the cells were seeded onto new 
culture dishes with inactivated MEFs. Colonies with signs of differentiation were removed 
mechanically. 
 




2.2.1.4 Feeder-free cultivation of hiPSCs 
 
In most experiments, hiPSCs were cultivated on culture dishes coated with growth factor reduced 
Geltrex™ in feeder-free Essential 8™ medium. At about 85-90% confluency the cells were 
passaged onto new plates. The cells were washed two times and incubated for 3 to 4 min with 
EDTA dissociation solution or Versene solution at room temperature. The small cell clusters or 
single cells were subsequently transferred in Essential 8™ medium onto new culture dishes 
coated with Geltrex™. After passaging, pro-survival compound or thiazovivin (Xu et al., 2010) 
was added to the medium to a final concentration of 5 μM. The medium was changed daily. 
 
2.2.1.5 Spontaneous differentiation of hiPSCs in vitro 
 
Mass culture for spontaneous differentiation experiments started when iPSCs reached 90-100% 
confluency. The cells were treated with 2.5 ml 200 U/ml collagenase type 4 for 5 minutes at 
37˚C. Cell colonies were cut with cell scraper into appropriate pieces. All colony pieces were 
collected with cell scraper from two culture plates and transferred to one medium added Petri 
dish. EBs were formed in suspension. The medium was changed to Iscove medium after 24 
hours and every 2 days until day 8. For the medium change, cell suspensions were collected from 
all dishes to one 15 ml tube, and then precipitated the cells by gravity (1-2 minutes). The 
supernatant was discarded and cell aggregates were transferred to new dishes. At day 8, about 50 
EBs were prepared for pellet collection, and the rest were used for plating. 1x 6 cm dish was 
coated with 0.1% gelatin for pellet collection, 2x 6 cm dishes with 4 coverslips each were coated 
for immunostaining at d8+5, 8+25. At day 8, about 50 EBs were prepared for pellet collection, 
and the rest were used for plating. The EBs were cultured in Iscove medium for another 25 days. 
The medium was changed every 2-3 days. Pellets were collected on d0, d8, d8+25. 
 
2.2.1.6 Directed differentiation of hiPSCs into CMs and CM digestion and culture 
 
A protocol for directed cardiac differentiation was used to obtain a high number of CMs as 
described previously (Lian et al., 2012; Lian et al., 2013). At about 95-100% confluency, the 




medium in undifferentiated hiPSCs cultivated under feeder-free conditions was replaced by 
cardiac differentiation medium supplemented with CHIR99021 at a final concentration of 4-10 
µM, a highly selective inhibitor of glycogen synthase kinase 3β. At day 2 (exactly 48 h later), the 
medium was carefully replaced by new cardiac differentiation medium supplemented with IWP2 
at a final concentration of 5 µM. At day 6, the medium was replaced with fresh cardiac 
differentiation medium without IWP2 and from day 8 on, the medium was replaced by B27 
medium. First beating cells could be observed at day 7-8 of differentiation.  
Around day 20, the more than 80% purify CMs were chosen for first digestion. Fresh 
collagenase 4 (200 U/ml) diluted with B27 medium was added to the cells and incubated for 30 
min to facilitate detachment of beating colonies from other cells. CM clusters after sedimentation 
for 5 minutes by gravity were treated with warmed 0.25% Trypsin-EDTA for 6-8 min at 37°C. 
The clusters were carefully pipetted up and down to singularize cells. The cell suspension was 
transferred in 15 ml Falcon tube with 2 ml cardiac digestion medium  containing 20% FBS and 
1x Pen/Strep, centrifuged for 5 min at 100-200 g, filtered out the big clusters which were not 
digested yet by using the 40 µm Falcon™ Cell Strainers, and resuspend in cardio digestion 
medium. The desired amount of cells was plated on Geltrex-coated 6-well plates (600000/well). 
After 60 days’ routine medium change with B27 medium every 2-3 days for maturation-inducing, 
the differentiated CMs were digested again in the same way as described above and used for 
further experiments. The single CMs were plated onto 0.1% gelatin-coated 3-cm tissue culture 
dishes and cultured further in the B27 medium for at least 14 days before used for AP 
measurements, and for at least 5 days before used for adenovirus infection for FRET experiments. 
 
2.2.1.7 Freezing and thawing of cultivated cells 
 
For cryopreservation, hiPSCs cultured on MEFs were treated with collagenase type 4 and 
dissected into small pieces as described before. hiPSCs cultured on Geltrex were treated with 
Versene Solution for 4-5 minute and dissociated into single cells and small clusters. The hiPSC 
clusters or single cells were transferred into 15 ml reagent and centrifuge tubes (Sarstedt) and 
centrifuged at 200 g for 5 min. After centrifugation, the supernatant was discarded and the cells 
were carefully resuspended in 1 ml freezing medium and transferred into cryovials (Greiner Bio-




one). The cells were kept overnight at -80°C in a freezing box (Thermo Fisher Scientific) 
containing isopropanol to allow controlled freezing at -1°C per min. The following day, frozen 
cells were transferred into liquid nitrogen. 
For thawing, the frozen cells were placed in a 37°C warm water bath. After thawing, the cells 
were immediately diluted drop-wise in 10 ml of cold DMEM/F-12 and centrifuged at 200 g for 5 
min. The supernatant was discarded and the cell pellet was resuspended in hESC or Essential 8™ 
medium and plated onto 6-cm culture dishes either coated with inactivated MEFs or with 
Geltrex™, respectively. 
 
2.2.2 Alkaline phosphatase staining 
 
One of the first evidence for successful somatic cell reprogramming is alkaline phosphatase 
activity. In reprogrammed cells, alkaline phosphatase expression is significantly increased. 
Alkaline phosphatase activity in hiPSCs was detected using an alkaline phosphatase staining kit 
according to the manufacturer’s instructions. Cells were washed with DPBS and subsequently 
fixed for 30 s using a fixation solution provided by the kit. Fixed cells were washed two times 
with distilled water and stained for 15 minutes at 37°C with a staining solution. After a final 
washing step with distilled water, cells were dried at room temperature. Alkaline phosphatase 
positive cells were stained in red. 
 
2.2.3 Genomic DNA isolation for DNA sequencing 
 
Feeder-free cultured iPSCs (without MEFs) were treated with TRlzol® reagent before genomic 
DNA isolation. The genomic DNA was isolated and purified using the TRlzol® reagent 
according to the manufacturer’s instructions. The concentration of the isolated DNA was 
measured with a Nanodrop spectrophotometer at 260 nm and 280 nm. For genomic DNA 
sequencing, the DNA sequence from the region of interest of RYR2 was initially amplified by 
PCR using the primer sets for CPVTa and CPVTd (Table 3). In each reaction, 50 ng of total 
genomic DNA was used. The PCR product was electrophoretically separated on a 2% agar gel 
and subsequently excised with a scalpel. The DNA fragments were then extracted from the agar 




gel using the QIAquick® gel extraction kit according to the manufacturer’s instructions using a 
refrigerated centrifuge. The DNA sequencing was performed by a commercial sequencing 
facility (Seqlab). 
 
2.2.4 Gene expression analyses 
 
2.2.4.1 RNA isolation 
 
For gene expression analyses, cultured cells were washed with DPBS three times. Depending on 
the density, cells were lysed with 300-500 µl RNA lysis buffer. Total RNA isolation and 
purification was done with the SV total RNA isolation system according to the manufacturer’s 
instructions. The concentration of the isolated RNA was measured with an Eppendorf 
BioPhotometer at 260 nm and 280 nm. The RNA was subsequently used for reverse transcription 
(RT) reaction or stored at -80°C. 
 
2.2.4.2 Reverse transcription reaction 
 
After RNA isolation, total mRNA was transcribed into complementary DNA (cDNA) using the 
enzyme reverse transcriptase. All components for one RT reaction are listed in Table 8. 
Table 8. Components for reverse transcription reaction 
Components for RT 20 µl final volume 
200 ng RNA + DEPC-treated H2O 10.2 µl 
10x PCR buffer II 2 µl 
25 mM MgCl2 4 µl 
100 nM dNTPs 0.8 µl 
RNase inhibitor (20 U/µl) 1 µl 
50 µM Oligo d(T)16 1 µl 
MuL V reverse transcriptase (50 U/µl) 1 µl 
 
The RT reaction was accomplished in a thermocycler (SensoQuest) using the following program: 
10 min                        22°C 




50 min                       42°C 
10 min                       95°C 
∞                              4°C 
The resulting cDNA was stored at -80°C. 
 
2.2.4.3 Polymerase chain reaction 
 
All components for one PCR to amplify certain cDNA fragments or templates are listed in Table 
9. 
Table 9: List of components for PCR. 
Components for PCR 25 µl final volume 
cDNA (template) 1 µl 
Nuclease-free H2O 15.3 μl 
5x Green GoTaq reaction buffer 5 μl 
Forward primer (10 μM) 1 μl 
Reverse primer (10 μM) 1 μl 
10 mM dNTPs 1.6 μl 
GoTaq G2 DNA polymerase (5 U/µl) 0.1 μl 
 
The reaction was performed in a thermocycler using the following standardized program: 
95 °C                               3 min 
95 °C                               30 s                  
50-60 °C                          30 s              30-38 cycles according to the primers used 
72 °C                               30 s 
72 °C                               10 min 
4 °C                                 ∞ 
 
2.2.4.4 Gel electrophoresis 
 




All amplified PCR products were analyzed by electrophoretic separation on a 1.5% or 2% agar 
gel. The particular sizes of the DNA fragments were determined by GeneRulerTM 100 bp Plus 
DNA Ladder. All results were documented under ultraviolet light with MultiImage Light Cabinet 
(Alpha Innotech Corporation). 
 
2.2.5 Immunofluorescence analyses 
 
Immunostainings were used to detect the expression and to show the localization of 
pluripotency-related proteins in undifferentiated hiPSCs, germ layer-specific proteins in 
differentiated hiPSCs, as well as cardiac-specific proteins in CMs. The hiPSCs and differentiated 
cells were initially cultivated on coverslips (Thermo Fisher Scientific). CMs were digested and 
the resulting single CMs were plated on 35-mm coverslips and further cultivated for at least 10 
days before fixation. The cells were washed with DPBS two times, followed by fixation in 4% 
PFA at room temperature for 20 minutes with three further washing steps. The cells which were 
stained for nuclear transcription factors (OCT4, SOX2, and NANOG) as well as the cardiac-
specific proteins cTNT, α-actinin, Cx43 and MLC2a were additionally treated with 0.1% 
Triton™ X-100/DPBS for 10 minutes at room temperature. Before antibody incubation, the fixed 
cells were blocked in 1% BSA overnight at 4°C. The cells were incubated with primary and 
subsequently with secondary antibodies, both diluted in 1% BSA for 1 hour at 37°C (NANOG at 
4°C overnight). The nuclei were stained with 0.4 μg/ml DAPI. The stained cells were washed 
with dH2O once before mounting with Fluoromount-G™. Fluorescent images were taken with a 
fluorescence microscope (Zeiss Observer.Z1 or Axio Imager.M2). 
 
2.2.6     Teratoma formation and analysis 
 
The experiment was approved by the Lower Saxony State Office for Consumer Protection and 
Food Safety (Az. 33.14.42502-04-113/09). Undifferentiated hiPSCs were mechanically dissected 
using a cell scraper and transferred into 200-300 µl DPBS. The cell clusters were injected 
subcutaneously into mice with deficiency in recombination activating gene 2 and gamma C 
(RAGC mice), which lack B cells, T cells, and natural killer cells. Teratomas were collected 




about three months after injection and fixed in phosphate buffered formalin (pH 7.0) for 4 hours 
at room temperature or 4°C overnight. After washing with dH2O, the teratomas were dehydrated 
and paraffinized using the Benchtop Tissue Processor 1020 (Leica Biosystems). The samples 
were embedded into paraffin using a tissue embedding system (Leica Biosystems) and processed 
into 6-µm sections with a microtome (Leica Biosystems). The histological sections were stained 
with hematoxylin and eosin (H&E) at the Department of Pathology at the University Medical 
Center Göttingen and subsequently analyzed under a light microscope (Zeiss). 
 
2.2.7     Karyotyping 
 
All hiPSCs were cultured on Geltrex™ before analyzing the karyotypes. The cells were treated 
with 100 ng/ml of the microtubule-depolymerizing drug colcemid (Karyomax® Colcemid® 
solution) for 16 hours. The supernatant containing detached cells was collected in a 15 ml 
reagent and centrifuge tube and the adherent cells were washed with DMEM once and 
subsequently treated with TrypLE™ for 1 minute at 37°C. Single cells were collected in the 15 
ml tube and centrifuged at 200 g for 5 min. The supernatant was discarded, leaving about 0.5 ml 
in which the cell pellet was resuspended by tapping carefully against the tube. Pre-warmed (37°C) 
KCl solution (0.075 M) was added drop-wise to the cell suspension up to 8 ml while shaking the 
tube carefully. After 45 min of incubation at 37°C, the cells were centrifuged and the supernatant 
was aspirated to a residue of 0.5 ml, in which the cells were resuspended again. Freshly prepared 
and pre-cooled (-20°C) methanol:acetic acid solution (1:3 freshly prepared) was then added 
drop-wise to the suspension while shaking the tube carefully. The cells were incubated on ice for 
10 minutes and then centrifuged. The fixation step was repeated two times. After the third 
fixation, the cells were resuspended in a final volume of about 2 ml to obtain an optimal density 
before dropped onto cold microscope slides. After air-drying, the chromosomes were stained 
with Giemsa solution (1/20 diluted in dH2O) for 5 minutes and washed twice with tap water. The 
stained chromosomes were counted under a light microscope (Zeiss Axio Imager, M2) and 
documented using the karyotyping analysis software Case Data Manager 6.0 (Applied Spectral 
Imaging, ASI). 
 




2.2.8     Flow cytometry 
 
Single CMs were obtained by digestion with 0.25% trypsin-EDTA. Three tubes of cells were 
prepared, one tube as negative control without staining, the other two as sample and negative 
control stained only with the second antibody, respectively. Cells were fixed with 4% PFA 
solution. To permeate the cell membrane, 0.1% Triton X-100/1% BSA was used to treat the cells 
for 15 minutes. The cells were incubated with the primary antibody (cTNT) overnight at 4oC. 
Alexa flour 488 was used as the second antibody for 30-45 minute at room temperature in the 
dark. One tube of cells were stained with the second antibody alone. The setup of BDTM 
FACSAria and the software of BDTM FACSDiva 6.1 were used, following the instruments of 
technician. 
 
2.2.9     Action potential measurements and data analysis 
 
All patch-clamp recordings were performed at room temperature using an EPC10 USB patch 
clamp amplifier together with the PatchMaster software (HEKATM). APs were measured with the 
ruptured-patch whole-cell current clamp technique. Spontaneous APs were recorded in RPMI 
1640 basal medium immediately after rupturing with self-pulled microelectrodes with 3-5 MΩ 
resistance (thin-wall capillaries, WPI). No current was injected into the cells. In some 
experiments, CMs were paced with 0.2, 0.4, 0.8, and 1.0 Hz for action potential duration (APD) 
analysis. The concentrations of four drugs recruited for analysis are: 1 µM for flecainide, 1 µM 
for dantrolene, 10 µM for rycal1, and 10 µM for rycal2. The CMs were kept in the incubator 
during the drug treatment for 1 to 2 hours. APs were analyzed using LabChart® 8 Pro software 
(AD Instruments) to determine the beating frequency, resting membrane potential (RMP), the 
maximal upstroke velocity (Vmax), the AP amplitude (APA), and the APDs at 50% and 90% of 
repolarization (APD50 and APD90). The parameters of 5 to 10 APs in a row were averaged for 
the analysis. The putative DADs were defined as the amplitude of a depolarization in RMP stage 
is more than 5 mV. The EADs were defined as abnormal depolarization occurs during phase of 
repolarization. The rhythmic cells were defined as show rhythmic beating and do not appear 
DADs, EADs and TAs (DAD- or EAD-induced). The Number of DADs/TAs was calculated by 




100*number of DADs and DAD-induced TAs/beating frequency /recording time. The number of 
EADs and EAD-induced TAs was analyzed in the same way. 
 
2.2.10     Microelectrode array experiments and data analysis 
 
For the multielectrode array (MEA) measurements, the CMs with purity more than 80% were 
dissociated with 0.25% Trypsin-EDTA for 8 min at 37°C, centrifuged for 5 min at 1,000 rpm and 
resuspended in digestion medium. Then, 50,000 cells were plated in each well of a 6-well MEA 
(60-6well MEA200/30iR-Ti-tcr, Multi Channel Systems) coated with 21 µg/cm2 Geltrex in 
DMEM/F-12 medium. After 24 h and every second day, the medium was changed to the B27 
medium. The cells on MEAs were cultured in B27 medium for 6 to 7 days before being used for 
recording. 
Field potentials (FPs) were recorded at a sampling rate of 1 kHz or 10 kHz with the MC-Rack 
software at 37°C by using the TC02 temperature controller (Multi Channel Systems). Every 
MEA was firstly recorded for 3 minutes at basal condition. Then, 100 nM ISO was added for 15 
min and the same MEA was recorded for another 3 minutes. The last MEA recording has been 
done for another 3 minutes after 1-2-hour-treatment with one of the investigated drugs. The 
MEA was kept in the incubator during the drug treatment. The concentrations of four drugs 
recruited for analysis are the same as used in patch-clamp experiments (1 µM flecainide, 1 µM 
dantrolene, 10 µM rycal1 and 10 µM rycal2). The frequency of FPs was determined by beats per 
minute from the last minute of the recording of each measurement. Based on recording results, 
ECG-like waveforms were analyzed for patterns similar to proarrhythmic events including PVC, 
VT. The arrhythmic cultures were defined as there are PVC-like events or VT-like events in the 
culture during 3 minutes recording time. The number of PVC-like events was quantified by the 
number of PVCs in every culture well divided by the recording time. Duration of VT-like events 
was normalized by dividing VT-like duration time to recording time. 
 
2.2.11     FRET measurements and data analysis 
 




To measure the cAMP dynamics with FRET biosensors, the sensors needed to be introduced into 
CMs. Adenoviruses carrying Epac1-camps and Epac1-camps-JNC were generated by the group 
of Prof. Nikolaev. CMs were plated onto coverslips at least 5 days before infection. The 
adenoviruses were mixed with B27 medium (MOI=10). CMs were incubated with the virus-
containing medium for 48 hours. Before starting FRET measurement, the cells were washed two 
times with RPMI 1640 medium to remove the virus. The cells were washed once with 300 µl of 
FRET buffer (in mM: 144 NaCl, 5.4 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, pH 7.3), and 300 µl of 
the same buffer were added to the chamber. CMs were identified by the presence of contractions. 
CMs were initially stimulated with 1 nM or 10 nM ISO. For PDE2, PDE3 and PDE4 inhibition, 
100 nM Bay 60-7550, 10 µM cilostamide and 10 µM rolipram were used respectively. To inhibit 
all PDEs, 100 µM IBMX was used. The measurements were performed with an inverted 
fluorescent microscope (Zeiss Axio Observer A1 or Olympus X71). Pictures were taken every 5 
seconds with 30-100 ms exposure time. Signals for CFP and YFP were measured. Three hundred 
µl of the desired compound solution (in FRET buffer) was added into the chamber as soon as the 
FRET ratio reached a stable baseline. FRET imaging data were analyzed offline using Origin 8 
software. The CFP and YFP intensities were copy-pasted into an Excel or Origin 8 spreadsheet 
to calculate the corrected FRET ratio. The bleedthrough of the donor fluorescence (CFP) into the 
acceptor (YFP) channel was corrected, in this study, the bleedthrough ratio = (YFP – 0.63 * CFP) 
/ CFP for Zeiss Axio Observer system or ratio = (YFP – 0.7 * CFP) / CFP for Olympus X71 
system. 
 
2.2.12    Statistical analysis 
 
Experimental data obtained from MEA, FRET and patch clamp analyses were presented as mean 
± standard error of mean (SEM). Arrhythmic cells and arrhythmic cultures were tested by using 
two-tailed Fisher’s exact test by a 2x2 contingency table. For comparing variables in patch-
clamp and FRET experiments, the two-tailed unpaired student’s t-test was applied. For 
comparing variables in MEA data, the two-tailed paired student’s t-test was applied. All the N 
numbers were listed in the figure legends. Statistical significance was expressed by the p-value 
represented as * (p < 0.05), ** (p < 0.01), and *** p < 0.001 or as † (p < 0.05), †† (p < 0.01), and 




††† (p < 0.001). All statistical analyses were performed by using GraphPad Prism®7, Office 







3.1 Generation of hiPSCs and proof of pluripotency 
 
The isolated fibroblasts from the CPVT patients were transduced with Sendai virus particles 
between passage 2 and 4. All the reprogramming protocols were referenced to CytoTune®-iPS 
Reprogramming Kit user manual. The first hiPSC colony-like areas appeared on day 11 after 
transduction. Several colonies resembling hiPSCs with respect to their morphology were picked 
mechanically and propagated further on new culture dishes coated with feeder cells. At least 
three independent cell lines for the CPVTa2 (isCPVTa2-1, -2, -3), CPVTa3 (isCPVTa3-1, -2, -3) 
and CPVTd1(isCPVTd1-4, -10, -11) patients were further characterized (Figure 11). The 
alkaline phosphatase was expressed in all generated hiPSC lines (Figure 11). Due to the heavy 
workload, this thesis is responsible for generation and characterization of isCPVTa2-1, -2, -3, 
isCPVTa3-1, -2, -3 and isCPVTd1-4, -10, -11 iPSC lines. 
 
 
Figure 11 Morphology and alkaline phosphatase staining of generated hiPSCs. The respectively 
iPSC clones showed typical hiPSCs morphology and alkaline phosphatase activity. Scale bar: 200 µm. 
 
3.1.1 Expression of pluripotency-related markers 
 
Cellular reprogramming involves an extensive remodeling of gene expression. The expression 





FOXD3 were investigated by semiquantitative RT-PCR analyses in the generated isCPVTa2, 
isCPVTa3, and isCPVTd1 iPSC lines and compared to their original fibroblasts (Figure 12). 
Obvious upregulation of these genes in all generated hiPSC clones was observed.  
 
 
Figure 12. Gene expression analysis of generated hiPSCs. The pluripotency-related genes SOX2, 
OCT4, NANOG, LIN28, GDF3, and FOXD3 were highly expressed in human embryonic stem cells and in 
the generated isCPVTa2, isCPVTa3 (A) and isCPVTd1 iPSC lines (B). These genes were lower 
expressed in the original fibroblasts as well as in MEFs. hES: human ESCs; Fib CPVTa2, Fib CPVTa3 
and Fib CPVTd1: fibroblasts from CPVT patients a2, a3 and d1. 
 
The presence of selected pluripotency markers was confirmed by immunofluorescent staining of 
derived iPSC lines. In all analyzed hiPSC lines isCPVTa2-1, -2, -3, isCPVTa3-1, -2, -3 and 
isCPVTd1-4, -10, -11, transcription factors such as NANOG, OCT4, and SOX2 were proved to 
be present and located in the nuclei. LIN28 was located in the cytoplasm, whereas SSEA4 and 






Figure 13. Immunostaining of pluripotency-related proteins in hiPSCs. All generated and analyzed 
iPSCs were positive for the transcription factors NANOG (in red), OCT4 (in red), and SOX2 (in red), as 
well as for the cytoplasmic located marker LIN28 (in red). SSEA4 (in green) and TRA-1-60 (in green), 
both located in the cell membrane were also detectable. The cell nuclei were stained with DAPI (in blue). 
Representative pictures from isCPVTa2-1, -2, -1, -1, -3, -1 for OCT4, SOX2, NANOG, LIN28, SEEA4, 
TRA1-60, respectively, and isCPVTa3-2, -2, -2, -1, -2, -3 were shown for OCT4, SOX2, NANOG, 
LIN28, SEEA4, TRA1-60, respectively. Scale bar: 50 µm. 
 
3.1.2 Differentiation potential in vitro and in vivo 
 
The differentiation potential of the generated hiPSCs in vitro and in vivo was determined by the 
spontaneous EB differentiation and teratoma formation, respectively. For the in vitro 
differentiation, the isCPVTa2, isCPVTa3, and isCPVTd1 cells were cultivated in suspension for 
8 days in Iscove medium. The cells formed multicellular aggregates known as EBs during this 
cultivation. The EBs were plated onto gelatin-coated culture dishes at day 8 for further 





time points (day 0, day 8, and day 8+25). The endodermal marker gene AFP and a late marker 
for hepatocytes, ALB, were expressed during differentiation. The mesodermal marker genes 
cTNT and α-MHC were expressed during EB differentiation. Both ectodermal marker genes SYP 
and TH were also expressed in each differentiated cell clone (Figure 14). 
 
 
Figure 14. Gene expression analysis of spontaneously differentiated hiPSCs. The analyzed iPSC lines 
isCPVTa2-, isCPVTa3 (A) and isCPVTd1 (B) were differentiated spontaneously in vitro and mRNA was 
isolated on day 0 (d0), day 8 (d8), and day 8+25 (d8+25) of differentiation. Ectodermal (AFP, ALB), 
mesodermal (α-MHC, cTNT) and endodermal (SYN, TH) marker genes were expressed during EB 
differentiation in a developmentally controlled manner. MEFs were used as negative control. 
 
Furthermore, all the three germ layer protein markers: the endodermal marker AFP, the 
mesodermal marker SMA as well as the neuroectodermal marker class III β-tubulin were 
detected by immunofluorescence staining among the differentiated cells from all analyzed iPSC 






Figure 15. Immunostaining of cells during spontaneous differentiation of hiPSCs. After 33-day 
spontaneous differentiation, markers for the three germ layers were detectable in differentiating cells of 
isCPVTa2, isCPVTa3 and isCPVTd1. The respective markers for endodermal, mesodermal and 
ectodermal are α-fetal protein (AFP), smooth muscle actinin (SMA) and class III β-tubulin. The cell 
nuclei were stained with DAPI (in blue). Scale bar: 50 µm. 
 
Subcutaneous injection of hiPSCs into immunodeficient RAGC mice was used to test their 
differentiation potential in vivo. The injected cells formed mature teratomas, which were 
analyzed histologically (Figure 16). The teratomas derived from all analyzed iPSC lines 
isCPVTa2, isCPVTa3 and isCPVTd1 contained derivatives of all three embryonic germ layers, 
which showed intestinal tissue as endodermal tissues (Figure 16A, E, I), cartilage (Figure 16B, 
F, J) and muscle cells (Figure 16C, G, K) as mesodermal tissue and neural rosettes representing 







Figure 16. Teratoma formation of hiPSCs after subcutaneous injection into immunodeficient 
RAGC mice. Teratomas developed from isCPVTa2 (A-D), isCPVTa3 (E-H), and isCPVTd1 (I-L) 
contained derivatives of all three embryonic germ layers: intestinal tissue with endodermal origin (A, E, 
I), mesoderm represented by cartilage (B, F, J) and muscle cells (C, G, K), and ectodermal neural 
rosettes (D, H, L). Scale bar: 100 µm. 
 
Taken together, the data show that the all generated and analyzed iPSC lines isCPVTa2, 
isCPVTa3, and isCPVTd1 were pluripotent. They expressed pluripotency-related markers on 
mRNA and protein levels. They had the potential to differentiate into derivatives of the three 




It was reported that iPSCs might develop chromosomal instability under long-term culture 
conditions (Stadtfeld et al., 2010). The generated hiPSCs in this study were used for 
differentiation experiments before a maximum of passage 30. To determine whether these cells 
exhibit numerical aberrations of their chromosomes, hiPSCs in passage≥30 were analyzed. A 





of undifferentiated cells, was not detected in the generated isCPVTa3-3. Representative diploid 
karyograms for isCPVTa3 were shown (Figure 17). 
 
 
3.1.4 Verification of the RYR2 point mutation in CPVTa- and CPVTd-iPSCs 
 
RYR2 gene is located on chromosome 1q43, and has 105 exons. The mutation of CPVTa2 and a3 
is located in exon 14, and the mutation of CPVTd1 is located in exon 99. The RYR2 gene region 
containing the mutant sites found in the CPVTa2, CPVTa3 and CPVTd1 patients were 
sequenced to confirm the genotypes in CPVT(a2, a3, d1)-iPSCs (Figure 18). The genomic DNA 
of the generated hiPSCs was isolated and sequenced approximately 150 bp up- and downstream 
of the predicted mutation positions within the RYR2 gene. All established hiPSCs lines of 
CPVTa2, CPVTa3 and CPVTd1 showed the mutation R420W and H4742Y, respectively, 
referred to the coding sequence of the RYR2 transcript variant (NCBI reference sequence: 
NM_001035.2). For CPVTa2 and a3, one allele carries a cytosine whereas the other allele carries 
a thymine. For CPVTd1, one allele carries a cytosine whereas the other allele carries a thymine. 
On the translational level, the missense mutation in CPVTa2 and CPVTa3 leads to the amino 




Figure 17. Diploid karyograms for generated hiPSCs. Respectively showed a normal karyotype 46, 







Figure 18. Verification of RYR2 point mutations in CPVTa- and CPVTd-iPSCs. All iPSC lines of 
CPVTa2 and CPVTa3 exhibited the point mutation on position 1258 referred to the coding sequence of 
the RYR2 transcript variant (NCBI: NM_001035.2), where a cytosine is replaced by a thymine on one 
of the alleles. All iPSC lines of CPVTd1 exhibited the point mutation on position 14224 referred to the 
coding sequence of the RYR2 transcript variant (NCBI: NM_001035.2), where a cytosine is replaced by 
a thymine on one of the alleles. The CPVTa2, a3 mutation leads to an amino acid change (arginine to 
tryptophan). The CPVTd1 mutation leads to an amino acid change (histidine to tyrosine).  
 






3.2.1 Differentiation of Ctrl- and CPVT-hiPSCs into CMs 
 
Ctrl- and CPVT-hiPSCs were differentiated into CMs using the cardiac-directed differentiation 
method (Figure 19A). First beating cells appeared at day 7–8 during directed cardiac 
differentiation of hiPSCs. The CMs were beating robustly around day 20, 12 days after culturing 
in the B27 medium.  
CMs with purity more than 50% analyzed by flow cytometry (Figure 19B) and visual 
observation were chosen for first digestion. The purity of CMs could reach more than 85% after 
first digestion by using physical purify skills mentioned before (2.2.1.6). No obvious differences 
between CPVTa2-, CPVTa3-, CPVTd1- and Ctrl-iPSC-CMs were observed regarding the 
differentiation efficiency. 
 
CMs after second digestion showed round, spindle-shaped, tri-, or multi-angular morphologies. 
The co-immunostaining with antibodies against the myofilament protein α-actinin, and the gap 
junction protein Cx43 showed that the CMs can conducting electrical signals between adjacent 
 
Figure 19. Directed differentiation procedures and differentiation efficiency. (A) Schematic 
presentation of cardiac-directed differentiation procedures of hiPSCs. (B) Shown are flow cytometry 
analysis of CMs stained with cTNT, demonstrating CMs used for further maturation-inducing culture 






cells. (Figure 20A). After three-month culture, the CMs had a high RYR2 (green) expression 
(Figure 20B). MLC2a and MLC2v co-immunostaining showed that majority of CMs were 
positive for MLC2v, indicating that they are ventricular-like CMs (Figure 20C). 
No obvious differences of the expression of cardiac-specific proteins between CPVTa2-, 
CPVTa3-, CPVTd1- and Ctrl-iPSC-CMs were observed.  
 
Figure 20. The differentiated CMs show normal sarcomere structure. Representitive co-
immunostaining showed that hiPSC-CMs (isCPVTa2-3) expressed structural myofilament protein α-
actinin (in red) and the gap junction protein Cx43 (in green) (A), Phalloidin (in red) and RYR2 (in green) 
(isCPVTa3-1) (B), and MLC2v (in green) and MLC2a (in red) (isCPVTa3-1) (C). Cell nuclei were 
stained with DAPI (in blue). Scale bar: 20 µm. 
 
3.2.2 Action potential morphology of Ctrl-CMs and CPVT-CMs 
 
In both Ctrl- and CPVT-iPSC-CM cultures, four different types of CMs with typical AP 
morphologies were detected by using the patch clamp technique (Figure 21). The typical APs of 





a rapid AP upstroke, an APA bigger than 90 mV. The ventricular-like CMs show a prominent 
plateau phase while atrial-like CMs lack the plateau phase, leading to a triangular-like shape. The 
parameter APD90/APD50 ≥ 2 for atrial CMs was used to distinguish ventricular-like from atrial-
like CMs (Fatima et al., 2011a). A nodal-like AP exhibited typically a less negative RMP (≥ –55 
mV), an APA smaller than 85 mV and a very slow maximal upstroke velocity (Vmax ≤ 5 V/s). 
Purkinje-like CMs were defined as prolonged APD especially for APD90 (Pallante et al., 2010). 
Typical morphologies of ventricular-like, nodal-like, atrial-like and Purkinje-like CMs were 
shown as following (Figure 21). 
 
Figure 21. Classification of differentiated CMs according to their AP morphologies. The APs of 
ventricular-like and atrial-like CMs were characterized by a rapid AP upstroke and a relative negative 
RMP. The difference between ventricular-like and atrial-like CMs was that ventricular-like CMs have a 
long plateau whereas atrial-like CMs show a triangular-like shape. The typical nodal-like CMs had a less 
negative resting membrane potential, a slower upstroke velocity, a smaller AP amplitude. The APDs 
(especially APD90) were prolonged in Purkinje-like CMs. 
 
Using the cardiac-directed differentiation method, the majority of the whole-cell patched cells 
(88-97%) were found to be ventricular-like cells in both Ctrl- and CPVT-iPSC-CM cultures 
(Figure 22) without significant differences among the cell lines analyzed. On average, less than 
4.2% (range 0-6.5%) of CMs were atrial-like CMs, whereas less than 3.3% (range 0-9%) of CMs 
were pacemaker-like CMs. In addition, the Purkinje-like CMs were very rare using this directed 
differentiation protocol. Only one Purkinje-like CM (APD90/APD50=7.7) was observed in 
CPVTc2-iPSC-CMs group. No statistical differences were observed between Ctrl- and CPVT-
iPSC-CM cultures regarding the CM subtype specification. Because CPVT was primarily caused 
by the abnormality in ventricular CMs, the directed differentiation and maturation-inducing 
protocol used in this study provides a reliable cell source of ventricular CMs that can be used for 






Figure 22. Percentage of ventricular-, atrial-, nodal-like and Purkinje-like CMs in Ctrl- and CPVT-
CMs. The majority of Ctrl- and CPVT-CMs (>87.88%)  was ventricular-like CMs (n=31-35 cells from 
each patient), based on single cell electrophysiological measurements of APs.  
 
To find out whether the different AP parameters of ventricular-like CMs were different in Ctrl-
CMs and CPVT-CMs, APs of single CMs were recorded in 3-month-old Ctrl-CMs and CPVT-
CMs (Figure 23A). For each patient, three independent iPSC lines were used for cardiac 
differentiation and phenotype characterization in order to avoid the difference due to one specific 
cell line.  
All the parameters were automatically quantified by using Lab chart software as described in 
2.2.8. There was no significant difference in APA, ranged from 96.28 mV to 101.9 mV between 
Ctrl-CMs and CPVT(a2, a3, b1, c1, c2, d1)-CMs, respectively (Figure 23B). Compared to Ctrl-
CMs (-63.13 ± 0.83, n=32), the RMP was significantly more positive in CPVTa3-CMs (-60.45 ± 
0.57, n=31), and CPVTd1-CMs (-59.83 ± 0.7, n=31), whereas CPVTa2-CMs showed also more 
positive (slightly but not significantly) RMP (-61.17 ± 0.59, n=32, p=0.06). No significant 
difference in RMP was observed between Ctrl-CMs and CPVT(b1, c1, c2)-CMs, respectively 
(Figure 23C). 
However, the Vmax were significant lower in CPVTa2-CMs (17.41 ± 1.17 V/s, n=32), CPVTa3-
CMs (17.75 ± 1.21 V/s, n=31), CPVTb1-CMs (17.34 ± 1.35 V/s, n=29), CPVTc2-CMs (17.87 ± 
1.42 V/s, n=29) and CPVTd1-CMs (11.52 ± 0.98 V/s, n=31) comparing to Ctrl-CMs (21.47 ± 
1.06 V/s, n=32). No significant difference in Vmax was observed between Ctrl-CMs and 
CPVTc1-CMs (21.13 ± 0.89 V/s, n=29) (Figure 23D). 
Because APD is related to frequency, only the whole-cell patched cells stimulated by the patch-
clamp generated pacing impulse were used for APD analysis. Due to the appearance of EADs in 
CPVTd1-CMs, it was impossible to pace the CPVTd1-CMs with 0.8 Hz, whereas other iPSC-





(1959 ± 204.4 ms, n=22) of CPVTd1-CMs paced with 0.2 Hz were significantly longer than 
APD50 (231.5 ± 23.98 ms, n=14) and APD90 (309.3 ± 26.26 ms, n=14) of Ctrl-CMs paced with 









Figure 23. Action potential characteristics of ventricular-like CMs. (A) The cartoon illuminated the 
measured parameters: APA, RMP, Vmax, APD50, and APD90. Statistic analysis of the AP parameters 
of ventricular-like Ctrl-CMs and CPVT-CMs in APA (B), RMP (C), Vmax (D), APD50/90 (E). Data are 
presented as mean ± SEM. For 0.8 Hz paced APD analysis experiments, cell numbers of Ctrl-CMs and 
CPVT(a2, a3, b1, c1, c2)-CMs equal to 16, 19, 17, 9, 12 and 14, respectively. For 0.2 Hz pacing 






3.2.3 The characteristics of CPVT-CMs in basal condition 
 
CPVT was associated with increased incidences of ventricular tachycardia and cardiac 
arrhythmias, which can be initiated by DAD- and EAD-induced TA. To investigate if there were 
differences in the severity of the arrhythmias in non-ISO stimulated Ctrl-CMs and CPVT-CMs, 
four prominent irregularities during spontaneous AP recordings in CPVT-CMs were compared to 
Ctrl-CMs: DADs, EADs, DAD- or EAD-induced TAs (Figure 24). 
Under the basal condition, only 8% of Ctrl-CMs (n=36 cells from 2 controls) showed arrhythmic 
beating and putative EADs or DADs and/or TAs, while about 20% for CPVTa2-CMs (n=35), 
16% CPVTa3-CMs (n=38), 18% CPVTb1-CMs (n=38), 30% for CPVTc1-CMs (n=36), 43% for 
CPVTc2-CMs (n=35) and 55% for CPVTd1-CMs (n=31) were observed to exhibit arrhythmic 
beating including DADs, EADs and TAs. Since no significant differences were observed 
between patient a2 and a3, as well as between patient c1 and c2, for further analysis, the data 
from a2 and a3, or from c1 and c2 were pooled (Figure 24B). 
 In the non-ISO stimulated condition, only CPVTd-CMs showed unique EADs and EAD-
induced TAs (Figure 24A), but the DADs and DAD-triggered activities were appeared in all 
non-ISO-stimulated groups no matter Ctrl-CMs or CPVT(a, b, c, d)-CMs. After quantification, 
only the number of DADs and TAs in CPVTd-CMs (8.9 ± 2.53, n=31) was significantly higher 
than in Ctrl-CMs (1.9 ± 1.16, n=36) (Figure 24B). Furthermore, the number of EADs and TAs 
in CPVTd-CMs (56.01 ± 24.14, n=31) was significantly higher than in Ctrl-CMs (0 ± 0, n=36) 
(Figure 24B).  
The beating frequencies were also analyzed. In comparison with Ctrl-CMs (0.49 ± 0.06 Hz), the 
beating frequency was significantly lower for CPVTa-CMs (0.23 ± 0.03 Hz) and CPVTd-CMs 
(0.15 ± 0.02 Hz) but not for CPVTb-CMs (0.50 ± 0.05 Hz) and CPVTc-CMs (0.55 ± 0.03 Hz) 














Figure 24. Patch-clamp results show EADs in non-ISO stimulated CPVTd-CMs. The 
representitive original traces of whole-cell patch-clamp recording for Ctrl-CMs, CPVT(a, b, c)-CMs 
and CPVTd-CMs, respectively are shown (A). Statistical parameters of arrhythmic cells, the number of 
DADs and TAs and the number of EADs and TAs showed unique significantly difference between 
Ctrl-CMs and CPVTd-CMs but not for CPVT(a, b, c)-CMs (B). Compared with Ctrl-CMs, the beating 
frequency was significantly lower for CPVTa-CMs and CPVTd-CMs (B). For the non-ISO stimulated 







MEA technology enables non-invasive measurements of local field potentials (Figure 25A) of 
electrically active cells and thus the activity of the underlying ion channels. MEA has been 
successfully used to study a homogeneous and electrically coupled population of CMs, and 
showed a similar ECG waveform. Every well of six-well MEA has nine electrodes (Figure 25A). 
The monolayer sheet of CMs (Figure 25A bottom right corner) was chosen for recording their 
field potentials. The original traces of nine electrodes displayed standard field potentials of the 
CMs in the well (also counts as one culture), which showed beating in the same rhythm (Figure 
25B). 
 
A                                                                   B 
 
  
Figure 25. The MEA technology is used to quantify arrhythmic events. The entity and layout of 
six-well MEA and the CMs were seeded as monolayer after second digestion (A). The traces of nine 
electrodes displayed standard field potentials and the CMs in the well (also counts as one culture) 
showed beating in the same rhythm (B). 
 
Lan et al. showed analysis of putative DADs by MEA and also provided the procedures to 
quantify arrhythmic events by using this technology (Lan et al., 2013). However, different from 







Figure 26. The representative original traces of MEA recording for Ctrl-CMs, CPVT(a, b, c)-CMs 
and CPVTd-CMs, respectively. The PVC-like and VT-like events are indicated with a red arrow. 
 
In the non-ISO stimulated condition, only 1.8% of the monolayer cultures of Ctrl-CMs (n=108 
from 2 cell lines per control, 2 controls, and 18 experiments) showed arrhythmic beating 
including PVC- or VT-like events. Similar results were observed for CPVTa-CMs (3.3%; n=92 
from 3 cell lines per patient, 2 patients, and 16 experiments), CPVTb-CMs (3.9%; n=77 from 2 
cell lines, and 13 experiments) and CPVTc-CMs (5.8%; n=104 from 2-4 cell lines per patient, 2 
patients, and 18 experiments). In contrast, 20.2% of the monolayer cultures of CPVTd-CMs 
(n=84 from 3 cell lines, and 14 experiments) showed arrhythmic beating including PVC- or VT-
like events (Figure 27A). Number of PVC-like events in CPVTd-CMs were significantly higher 
when compared to Ctrl-CMs. Nevertheless, the Number of PVC-like events in CPVT(a, b, c)-
CMs had no significantly differences in comparison to Ctrl-CMs (Figure 27B). Similarly, the 





CPVTc-CM cultures when compared to Ctrl-CM cultures under basal conditions (Figure 27C). 
In addition, compared to Ctrl-CMs, the beating frequency was significantly lower in CPVTa-
CMs, CPVTc-CMs, and CPVTd-CMs but significantly higher in CPVTb-CMs under basal 









Figure 27. MEA results presented arrhythmic events in non-ISO stimulated CPVTd-CMs. 
Statistical parameters of arrhythmic cultures, the number of PVC-like events, and VT-like duration show 
unique significant differences between Ctrl-CMs and CPVTd-CMs but not for CPVT(a, b, c)-CMs (A, B, 
C). Compared with Ctrl-CMs, the beating frequency is significantly lower for CPVTa-CMs, CPVTc-
CMs, and CPVTd-CMs, but higher for CPVTb-CMs (D). For the non-ISO stimulated MEA experiments, 
culture numbers of Ctrl-CMs and CPVT(a, b, c, d)-CMs equal to 108, 92, 77, 104, and 84, respectively. 
 
3.2.4 CPVT-CMs after ISO stimulation recapitulated the disease phenotype of CPVT  
 
Because arrhythmias in CPVT manifest after exercise or emotional stress, the next step evaluates 
whether the activation of the β-AR pathway in CPVT-CMs can recapitulate the disease 
phenotype of CPVT. The Ctrl-CMs show regular beating after ISO stimulation. After 100 nM 
ISO stimulation, CPVT(a, b, c)-CMs presented dozens of DADs and DAD-induced TAs while 






Figure 28. CPVT-CMs presented DADs, EADs and TAs after ISO stimulation. The Ctrl-CMs show 
regular beating after ISO stimulation. The representative CPVTa3-CM presented dozens of DADs and 
DAD induced TAs after ISO stimulation. The CPVTd-CMs still presented EADs after ISO stimulation. 
 
First, patch clamp analyses showed that the percentage of arrhythmic cells significantly 
increased in CPVTa-CMs (84.3%, n=32), CPVTb-CMs (93.7%, n=16), CPVTc-CMs (94.6%, 
n=37) and CPVTd-CMs (93.7%, n=16) when compared to their respective basal conditions and 
to Ctrl-CMs after ISO stimulation (Figure 29). To further assess arrhythmia severity, the number 
of DADs and DAD-induced TAs together with the number of EADs and EAD-induced TAs were 
quantified. The number of DADs and DAD-induced TAs significantly increased in ISO-treated 
CPVTa-CMs (44.38 ± 9.93, n=32), CPVTb-CMs (63.89 ± 13.9, n=16), and CPVTc-CMs (48.77 
± 7.1, n=37) but not in Ctrl-CMs (1.06 ± 0.68, n=22) and CPVTd-CMs (8.58 ± 3, n=16), 
suggesting that there might be different arrhythmogenesis mechanisms caused by specific 
mutations (Figure 29). EADs and EAD-induced TAs especially occurred only in CPVTd-CMs 





mechanisms. The beating frequencies of Ctrl-CMs and CPVT(a, b, c, d)-CMs showed a very 
complex profile due to the existence of lots of DADs and EADs. The ISO treatment resulted in 
increased beating frequency in Ctrl- and CPVTa- and CPVTd-CMs, but not in CPVTb- and 
CPVTc-CMs (Figure 29). The not-increased beating frequency in CPVTb- and CPVTc-CMs 
after the ISO treatment is due to the strongly induced irregular beating, including the stopped 




Figure 29. Mutation-specific profiles of DADs, EADs and TAs after ISO stimulation. Shown are 
comparison of arrhythmic cells, numbers of DADs and TAs, EADs and TAs, and beating frequency in 
Ctrl-CMs and CPVT(a, b, c, d)-CMs after ISO-treatment. For the ISO-challenged experiments, numbers 
of Ctrl-CMs and CPVT(a, b, c, d)-CMs equal to 22, 32, 16, 37 and 16, respectively. 
 
Second, MEA recordings were performed in Ctrl- and CPVT-CMs after ISO (100 nM) 





which exhibited PVC-like and VT-like events, whereas Ctrl-CMs displayed normal waveforms 
(Figure 30A). 
Application of 100 nM ISO for 15 minutes, the same concentration using for patch-clamp 
experiments, significantly increased the percentage of arrhythmic cultures in CPVTa-CMs 
(54.3%, n=89), CPVTb-CMs (48%, n=77), CPVTc-CMs (54.8%, n=97) and CPVTd-CMs (50%, 
n=83) compared to their corresponding basal conditions or to ISO-stimulated Ctrl-CMs (3.8%, 
n=108) (Figure 30B). β-adrenergic stimulation was also found to severely exacerbate the 
presentation of PVC-like events in MEA recordings in CPVTa-CMs (24.66 ± 4.264, n=92), 
CPVTb-CMs (21.62 ± 4.03, n=77), CPVTc-CMs (27.54 ± 4.74, n=104) and CPVTd-CMs (15.36 
± 3.037, n=84) but not in Ctrl-CMs (1.27 ± 0.9, n=108).  
In addition, the ISO treatment resulted in the significantly longer duration of VT-like events in 
CPVTa-CMs (262.2 ± 68.69 s/hour), CPVTb-CMs (174.4 ± 62.44 s/hour), CPVTc-CMs (292.5 ± 
83.48 s/hour) and CPVTd-CMs (352.7 ± 93.04 s/hour) when compared to their corresponding 
basal conditions (Figure 30B).  
It is interesting to notice that the frequencies of CPVTa-CMs (0.656 ± 0.016 Hz) and CPVTd-
CMs (0.68 ± 0.01 Hz) were significantly lower compared to Ctrl-CMs (0.82 ± 0.007 Hz) in the 
ISO-treated conditions even though all CPVT(a, b, c, d)-CMs and Ctrl-CMs showed dramatically 
increased frequencies after the ISO treatment in relation to their corresponding basal conditions 
(Figure 30B). 
These findings are correspond with the patch-clamp results, which confirm that the MEA 
technology can be additionally used to investigate the arrhythmia generated by CMs derived 
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Figure 30. CPVT-CMs generated plenty of PVC-like and VT-like events after ISO stimulation. 
The MEA recording of ISO-treated Ctrl-CMs shows rhythmic beating. Representative traces with 
PVC-like and VT-like events in CPVT-CMs after ISO incubation for 15 minutes are shown (A). 
Compared to their corresponding basal condition, all the four parameters: arrhythmic cultures, the 
number of PVC-like events, duration of VT-like events, and beating frequency significantly increased 





parameters: arrhythmic cultures, number of PVC-like events, and duration of VT-like events 
significantly increased in CPVT-CMs after ISO stimulation. After ISO treatment, the beating 
frequencies were significantly lower in CPVT(a, d)-CMs compared with Ctrl-CMs (B). For the ISO-
challenged MEA experiments, culture numbers of Ctrl-CMs and CPVT(a, b, c, d)-CMs equal to 108, 
92, 77, 104, and 84, respectively. 
 
3.3 Application of CPVT-CMs for drug testing 
 
3.3.1 Antiarrhythmic effects of flecainide 
 
Flecainide is a class antiarrhythmic agent used to prevent and treat tachyarrhythmias. Watanabe 
et al. reported that flecainide prevented CPVT in mice and humans by decreasing RYR2 opening 
probability (Watanabe et al., 2009). Meanwhile, Liu N et al. reported that flecainide had an 
antiarrhythmic effect in a CPVT mouse model by increasing the threshold for triggered activity 
(through its sodium channel blocking effect) (Liu et al., 2011). Recently, Itzhaki et al. showed 
that flecainide completely eliminated or significantly decreased DADs and DAD-induced TAs in 
patient-specific CPVT (M4109R)-hiPSCs-CMs (Itzhaki et al., 2012). To test whether flecainide 
had different antiarrhythmic effects on CPVT(a, b, c, d)-CMs harboring different mutations 
(R420W, A2254V, E4076K, and H4742Y), two electrophysiological methods were applied to 
assess the arrhythmic events in Ctrl-CMs and CPVT(a, b, c, d)-CMs, which were challenged by 
100 nM ISO and then incubated with 1 µM flecainide for one to two hours. 
Patch-clamp analysis showed that the percentages of arrhythmic cells decreased significantly in 
CPVTa-CMs (22.58%, n=31) and CPVTc-CMs (46.43%, n=28) after flecainide treatment, but 
not significantly in CPVTb-CMs (69.23%, n=13) and CPVTd-CMs (64.29%, n=14) compared to 
their respective ISO-challenged conditions (Figure 31A). The number of DADs and DAD-
induced TAs significantly decreased in CPVTa-CMs (4.4 ± 1.59, n=31), CPVTb-CMs (16.86 ± 
5.8, n=13), CPVTc-CMs (13.54 ± 3.69, n=32), but not in CPVTd-CMs (12.05 ± 5.99, n=14), 
when compared to their respective ISO-challenged conditions (Figure 31B). Interestingly, 
Number of EADs and EAD-induced TAs increased in CPVTd-CMs (91.35 ± 34.78, n=14) after 
flecainide incubation (Figure 31). The beating frequencies were decreased in Ctrl-CMs and in 






MEA recordings showed the significantly decreased percentages of arrhythmic cultures after 
flecainide treatment in CPVTa-CMs (4.1%), CPVTb-CMs (0%), CPVTc-CMs (6.6%) but not in 
CPVTd-CMs (16.6%), when compared to respective ISO-challenged CPVTa-CMs (58.3%), 
CPVTb-CMs (54.1%), CPVTc-CMs (63.3%), and CPVTd-CMs (44.4%) (Figure 32A). The 
number of PVC-like events significantly decreased in CPVTa-CMs (1.639 ± 1.639), CPVTb-
 
Figure 31. Systematic assessment of antiarrhythmic effects of flecainide by patch-clamp technique. 
(A) Summary of the percentage of CPVT- and Ctrl-CMs displaying arrhythmic beating in ISO-challenged 
condition and flecainide-treated condition. (B) Number of DADs and TAs significantly decreased in 
CPVT(a, b, c)-CMs but not in CPVTd-CMs after treated with flecainide. (C) Number of EADs and TAs 
increased in CPVTd-CMs after flecainide incubation. (D) The beating frequencies in all Ctrl-CMs and 
CPVT(a, b, c, d)-CMs decreased after flecainide treatment. For the flecainide-treated patch-clamp 






CMs (0 ± 0), CPVTc-CMs (1.28 ± 0.89), and CPVTd-CMs (2.56 ± 1.78) after flecainide 
treatment, when compared to respective ISO-challenged CPVTa-CMs (25.75 ± 5.54), CPVTb-
CMs (19.12 ± 5.98), CPVTc-CMs (41.9 ± 12.22), and CPVT-d-CMs (18.93 ± 7.26) (Figure 
32B). 
Moreover, the VT-like events in MEA recording disappeared in CPVT(a, b, c)-CMs but not in 
CPVTd-CMs (95.91 ± 95.91 s/hour) after flecainide incubation (Figure 32C). In addition, the 
flecainide treatment resulted in significantly reduced beating frequencies of Ctrl-CMs and 
CPVT(a, b, c, d)-CMs (Figure 32D). 
These results indicate that flecainide had antiarrhythmic effects on CPVT(a, b, c)-CMs, but 







Figure 32. MEA data confirmed antiarrhythmic effects of flecainide for CPVT(a, b, c)-CMs. (A) 
Percentage of cultures in Ctrl-CMs and CPVT-CMs which displayed PVC-like and VT-like events. 
Notably, flecainide reduced the arrhythmic cultures in CPVT(a, b, c)-CMs but not in CPVTd-CMs when 
compared to the cells only challenged with ISO, respectively. (B) Number of PVC-like events 
significantly decreased in all CPVT-CMs after flecainide treatment. (C) VT-like events disappeared in 
CPVT(a, b, c)-CMs but not in CPVTd-CMs after flecainide treatment. (D) Beating frequencies decreased 
significantly in both Ctrl-CMs and CPVT-CMs. For the flecainide-treated MEA experiments, culture 
numbers of Ctrl-CMs and CPVT(a, b, c, d)-CMs equal to 24, 24, 24, 30 and 18, respectively. 
 
3.3.2 Antiarrhythmic effects of dantrolene 
 
Dantrolene is a specific agent for the treatment of malignant hyperthermia. There were several 
publications demonstrating that dantrolene has antiarrhythmic effects on CPVT (Jung et al., 2012; 





CPVT(a, b, c, d)-CMs harboring different mutations (R420W, A2254V, E4076K and H4742Y), 
two electrophysiological methods (Figure 33, Figure 34) were used to assess the arrhythmic 
events of Ctrl-CMs and CPVT(a, b, c, d)-CMs, which were challenged by 100 nM ISO and then 
incubated with 1 µM dantrolene for one to two hours. 
Patch-clamp analysis showed that the percentage of arrhythmic cells decreased significantly in 
CPVTa-CMs (20.7%, n=29) and CPVTc-CMs (31%, n=32) after dantrolene treatment, but not in 
CPVTb-CMs (70%, n=10) and CPVTd-CMs (84.6%, n=13), compared to their respective ISO-
challenged conditions (Figure 33A). The number of DADs and DAD-induced TAs significantly 
decreased in CPVTa-CMs (2.9 ± 1.2, n=29), CPVTb-CMs (11.28 ± 6, n=10), CPVTc-CMs (4.07 
± 1.4, n=32), but increased in CPVTd-CMs (11.98 ± 3.9, n=13), compared to their respective 
ISO-challenged conditions (Figure 33B). Interestingly, Number of EADs and TAs increased in 
CPVTd-CMs (49.87 ± 23.59, n=13) after dantrolene incubation (Figure 33C). The beating 












Figure 33. Systematic assessment of antiarrhythmic effects of dantrolene by patch-clamp technique. 
(A) Summary of the percentage of CPVT-CMs and Ctrl-CMs displaying arrhythmic beating in ISO-
challenged condition and dantrolene-treated condition. (B) Number of DADs and TAs significantly 
decreased in CPVT(a, b, c)-CMs but not in CPVTd-CMs after treated with dantrolene. (C) Number of 
EADs and TAs increased in CPVTd-CMs after dantrolene incubation. (D) The beating frequencies in 
CPVTc-CMs increased significantly after dantrolene treatment. For the dantrolene-treated patch-clamp 







MEA recordings showed the significantly decreased percentages of arrhythmic cultures after 
flecainide treatment in CPVTa-CMs (4.2%), CPVTb-CMs (0%), CPVTc-CMs (0%) and CPVTd-
CMs (20.1%), when compared to respective ISO-challenged CPVTa-CMs (50%), CPVTb-CMs 
(38.9%), CPVTc-CMs (53.6%), and CPVTd-CMs (54.2%) (Figure 34A). The number of PVC-
like events significantly decreased in CPVTa-CMs (0.7 ± 0.7), CPVTb-CMs (0 ± 0), CPVTc-
CMs (0 ± 0), and CPVTd-CMs (5.6 ± 2.9) after flecainide treatment, when compared to 
respective ISO-challenged CPVTa-CMs (35.3 ± 12.6), CPVTb-CMs (18.26 ± 7.4), CPVTc-CMs 
(16.71 ± 4.6), and CPVT-d-CMs (10.88 ± 4.9) (Figure 34B). 
Moreover, the VT-like events in MEA recording disappeared in CPVT(a, b, c)-CMs but not in 
CPVTd-CMs (150 ± 150 s/hour) after dantrolene incubation (Figure 34C). In addition, the 
flecainide treatment resulted in significantly reduced beating frequencies in Ctrl-CMs and 
CPVT(a, b, d)-CMs (Figure 34D). 
These results indicate that dantrolene had antiarrhythmic effects on CPVT(a, b, c)-CMs but 









Figure 34. MEA data confirmed antiarrhythmic effects of dantrolene for CPVT(a, b, c)-CMs. (A) 
Percentage of cultures in Ctrl-CMs and CPVT-CMs which displayed PVC-like and VT-like events. 
Dantrolene reduced the arrhythmic cultures in CPVT(a, b, c, d)-CMs when compared to the cells only 
challenged with ISO, respectively. (B) Number of PVC-like events significantly decreased in CPVT(a, b, 
c)-CMs, but not in CPVTd-CMs after dantrolene treatment. (C) VT-like events disappeared in CPVT(a, b, 
c)-CMs, but not in CPVTd-CMs after dantrolene treatment. (D) Beating frequencies decreased 
significantly in Ctrl-CMs and CPVT(a, b, d)-CMs, but not in CPVTc-CMs when compared with ISO-
challenged condition, respectively. For the dantrolene-treated MEA experiments, culture numbers of Ctrl-
CMs and CPVT(a, b, c, d)-CMs equal to 30, 24, 18, 28 and 24, respectively. 
 
3.3.3 Antiarrhythmic effects of rycal1 
 
RYR channel stabilizers (rycals) restore the normal function of RYR channels and are not RYR2 





pharmacological company for this study. To test whether rycal1 has antiarrhythmic effects on 
CPVT(a, b, c, d)-CMs harboring different mutations (R420W, A2254V, E4076K and H4742Y), 
two electrophysiological methods (Figure 35, Figure 36) were applied to assess the arrhythmic 
events of Ctrl-CMs and CPVT(a, b, c, d)-CMs, which were challenged by 100 nM ISO and then 
incubated with 10 µM rycal1 for one to two hours. 
Patch clamp analysis showed that the percentages of arrhythmic cells decreased significantly in 
CPVTa-CMs (25%, n=32), CPVTb-CMs (41.7%, n=12), CPVTc-CMs (32.4%, n=37) and 
CPVTd-CMs (60%, n=15) after rycal1 treatment, when compared to their respective ISO-
challenged conditions (Figure 35A). The number of DADs and DAD-induced TAs significantly 
decreased in CPVTa-CMs (5.7 ± 2, n=32), CPVTb-CMs (10.3 ± 5.4, n=12), CPVTc-CMs (5.1 ± 
1.8, n=37), but increased in CPVTd-CMs (13.6 ± 5.8, n=15), when compared to their respective 
ISO-challenged conditions (Figure 35B). Interestingly, Number of EADs and EAD-induced TAs 
increased in CPVTd-CMs (56.3 ± 32.6, n=15) after rycal1 incubation (Figure 35C). The beating 
frequencies decreased significantly in CPVTa-CMs after rycal1 treatment, increased but not 








Figure 35. Systematic assessment of antiarrhythmic effects of rycal1 by patch-clamp technique. (A) 
Summary of the percentage of CPVT- and Ctrl-CMs displaying arrhythmic beating in ISO-challenged 
condition and flecainide-treated condition. (B) Number of DADs and TAs significantly decreased in 
CPVT(a, b, c)-CMs but increased in CPVTd-CMs after treated with rycal1. (C) Number of EADs and 
TAs increased in CPVTd-CMs after rycal1 incubation. (D) The beating frequencies in CPVTa-CMs 
decreased significantly after rycal1 treatment. For the rycal1-treated patch-clamp experiments, cell 
numbers of Ctrl-CMs and CPVT(a, b, c, d)-CMs equal to 17, 32, 12, 37 and 15, respectively. 
 
MEA recordings showed the significantly decreased percentages of arrhythmic cultures after 
rycal1 treatment in CPVTa-CMs (0%) and CPVTb-CMs (0%), but not in CPVTc-CMs (5.6%) 
and CPVTd-CMs (33.3%), when compared to respective ISO-challenged CPVTa-CMs (66.7%), 
CPVTb-CMs (41.7%), CPVTc-CMs (33.3%), and CPVTd-CMs (61.1%) (Figure 36A). The 
number of PVC-like events significantly decreased in CPVTa-CMs (0 ± 0) and CPVTc-CMs (0 





compared to respective ISO-challenged CPVTa-CMs (16.95 ± 4.1), CPVTb-CMs (28 ± 15.77), 
CPVTc-CMs (25.42 ± 10.66), and CPVT-d-CMs (23.23 ± 8.4) (Figure 36B). 
Moreover, the VT-like events in MEA recording disappeared in CPVT(a, b)-CMs, but not in 
CPVTc-CMs (50 ± 50 s/hour) and CPVTd-CMs (216 ± 122.3 s/hour) after rycal1 incubation 
(Figure 36C). In addition, the rycal1 treatment resulted in significantly reduced beating 
frequencies in Ctrl-CMs and CPVT(a, b, d)-CMs, but not in CPVTc-CMs (Figure 36D). 
These results indicated that rycal1 had antiarrhythmic effects on CPVT(a, b, c)-CMs but minor 








Figure 36. MEA data confirmed antiarrhythmic effects of rycal1 for CPVT(a, b, c)-CMs. (A) Rycal1 
reduced the arrhythmic cultures (displaying PVC-like and VT-like events) in CPVT(a, b)-CMs when 
compared to the cells only challenged with ISO, respectively. (B) Number of PVC-like events 
significantly decreased in CPVT(a, c)-CMs, but not in CPVT(b, d)-CMs after rycal1 treatment. (C) VT-
like events disappeared in CPVT(a, b)-CMs, but not in CPVT(c, d)-CMs after rycal1 treatment. (D) 
Beating frequencies decreased significantly in Ctrl-CMs and CPVT(a, b, d)-CMs, but not in CPVTc-CMs 
when compared with their ISO-challenged condition, respectively. For the rycal1-treated MEA 
experiments, culture numbers of Ctrl-CMs and CPVT(a, b, c, d)-CMs equal to 30, 24, 12, 18 and 18, 
respectively. 
 
3.3.4 Antiarrhythmic effects of rycal2 
 
To test whether rycal2 has different antiarrhythmic effects on CPVT(a, b, c, d)-CMs harboring 
different mutations (R420W, A2254V, E4076K and H4742Y), two electrophysiological methods 





c, d)-CMs, which were challenged with 100 nM ISO and then incubated with 10 µM rycal2 for 
one to two hours. 
Patch clamp analysis showed that the percentages of arrhythmic cells decreased significantly in 
CPVTa-CMs (29.6%, n=27), CPVTb-CMs (57.1%, n=14) and CPVTc-CMs (38.9%, n=36) after 
rycal2 treatment, but not significantly in CPVTd-CMs (64.7%, n=17) compared to their 
respective ISO-challenged conditions (Figure 37A). The number of DADs and DAD-induced 
TAs significantly decreased in CPVTa-CMs (5.2 ± 2, n=27), CPVTb-CMs (5.2 ± 2.3, n=14), 
CPVTc-CMs (4.9 ± 1.8, n=36), but not in CPVTd-CMs (9.3 ± 3.3, n=17), when compared to 
their respective ISO-challenged conditions (Figure 37B). Interestingly, Number of EADs and 
EAD-induced TAs decreased slightly but not significantly in CPVTd-CMs (13.67 ± 7.9, n=17) 
after rycal2 incubation (Figure 37C). Notably, there were some EADs and TAs in CPVTb-CMs 
and CPVTc-CMs after rycal2 incubation (Figure 37C). The beating frequencies were 
significantly decreased in CPVTa-CMs (0.25 ± 0.05 Hz) and CPVTb-CMs (0.15 ± 0.04 Hz) after 








Figure 37. Systematic assessment of antiarrhythmic effects of rycal2 by patch-clamp technique. (A) 
Summary of the percentage of CPVT- and Ctrl-CMs displaying arrhythmic beating in ISO-challenged 
condition and flecainide-treated condition. (B) Number of DADs and TAs significantly decreased in 
CPVT(a, b, c)-CMs but not in CPVTd-CMs after treated with rycal2. (C) There were some EADs and 
TAs in CPVTb-CMs and CPVTc-CMs after rycal2 incubation. (D) The beating frequencies in CPVT(b, 
c)-CMs decreased significantly after rycal2 treatment. For the rycal2-treated patch-clamp experiments, 
cell numbers of Ctrl-CMs and CPVT(a, b, c, d)-CMs equal to 13, 27, 14, 36 and 17, respectively. 
 
MEA recordings showed the significantly decreased percentages of arrhythmic cultures after 
rycal2 treatment in CPVTa-CMs (5%), CPVTb-CMs (0%), CPVTc-CMs (3.6%) but not in 
CPVTd-CMs (29.2%), when compared to respective ISO-challenged CPVTa-CMs (40%), 
CPVTb-CMs (52.2%), CPVTc-CMs (60.7%), and CPVTd-CMs (41.7%) (Figure 38A). The 





(0 ± 0), CPVTc-CMs (0.68 ± 0.68) but not in CPVTd-CMs (2.19 ± 1.6) after rycal2 treatment, 
when compared to respective ISO-challenged CPVTa-CMs (19.83 ± 9.4), CPVTb-CMs (23.51 ± 
7), CPVTc-CMs (24.34 ± 8.19), and CPVT-d-CMs (11.25 ± 4.5) (Figure 38B). 
Moreover, the VT-like events in MEA recording disappeared in CPVT(a, b, c)-CMs, but 
increased in CPVTd-CMs (437.5 ± 224.6 s/hour) after rycal2 incubation (Figure 38C). In 
addition, the rycal2 treatment resulted in significantly reduced beating frequencies in Ctrl-CMs 
and CPVT(a, b, d)-CMs, but significantly increased in CPVTc-CMs (0.9 ± 0.04 Hz) (Figure 
38D). 
These results indicated that rycal2 had antiarrhythmic effects on CPVT(a, b, c)-CMs but minor 







Figure 38. MEA data confirmed antiarrhythmic effects of rycal2 for CPVT(a, b, c)-CMs. (A) Rycal2 
significantly reduced the arrhythmic cultures (displaying PVC-like and VT-like events) in CPVT(a, b, c)-
CMs, but not in CPVTd-CMs when compared to the cultures only challenged with ISO, respectively. (B) 
Number of PVC-like events significantly decreased in CPVT(a, b, c)-CMs but not in CPVTd-CMs after 
rycal2 treatment. (C) VT-like events disappeared in CPVT(a, b, c)-CMs, but increased in CPVTd-CMs 
after rycal2 treatment. (D) Beating frequencies decreased significantly in Ctrl-CMs and CPVT(a, b, d)-
CMs, but increased significantly in CPVTc-CMs when compared to ISO-challenged condition, 
respectively. For the rycal2-treated MEA experiments, culture numbers of Ctrl-CMs and CPVT(a, b, c, 
d)-CMs equal to 24, 20, 23, 28 and 24, respectively. 
 







β-adrenergic signaling pathway plays a central role in regulating the chronotropic, inotropic and 
lusitropic effects, and initiating CPVT. Previously published data demonstrated that the cAMP-
degrading enzyme PDEs were upregulated or downregulated in different kinds of cardiovascular 
diseases (Mehel et al., 2013; Smith et al., 1998; Wu et al., 2015). However, the cAMP dynamic 
and the role of PDEs have not been investigated in CPVT. 
In this project, cAMP levels and activity of PDE2, 3 and 4 in CPVT(a, b, c, d)-CMs were 
investigated and compared with Ctrl-CMs. Levels of cAMP in cytosol and at the RYR2 
microdomain in CPVT(a, b, c, d)-CMs and Ctrl-CMs had been examined in cooperation with 
Prof. Nikolaev. Several cAMP microdomains have been proposed in CMs so far; one of them is 
located at RYR2. In this study, the biosensors Epac1-camps and Epac1-camps-JNC were used to 
study the cAMP levels in cytosol and at the RYR2 microdomain, respectively. The biosensor 
Epac1-camps was generated by the group of Nikolaev in 2004 (Nikolaev et al., 2004), while the 
sensor Epac1-camps-JNC was recently generated by Konrad Götz in his doctoral thesis (Götz, 
2014). While Epac1-camps is distributed throughout the cytosol, Epac1-camps-JNC is associated 
with RYR2 in the SR membrane. 
 
3.4.1 ISO concentration-dependent FRET reaction  
 
In the adult human heart, the β1-AR is the predominant receptor (Brodde, 1991; Wallukat, 2002), 
which is located all over the cell surface, while β2-AR is only located in the T-tubules of CMs 
(Nikolaev et al., 2010).  It has been reported that in adult murine CMs, β2-AR-generated cAMP 
is more locally confined near the RYR2, while β1-AR-generated cAMP defuses broadly in the 
cell (Nikolaev et al., 2006; Nikolaev et al., 2010). Due to the relative lower maturation degree, 
the absence of T-tubules in iPSC-CMs is associated with the lack of regular organization of L-
type Ca2+ channel-RYR2 complexes (Kane et al., 2015). Therefore, both the β1-AR and the β2-
AR were stimulated by ISO simultaneously in this study. 
The β-AR system is playing a predominant role in functional regulation of the heart by mediating 
the effects of endogenous catecholamines. To investigate whether the Epac1-camps- and Epac1-
camps-JNC-transfected Ctrl- and CPVT-CMs had a concentration-dependent reaction to 





stimulation with 1 nM (Figure 39A, B) or 10 nM (Figure 39D, E) ISO as a percentage of the 
maximum change of the measurement (after IBMX treatment) was investigated by using both 
Epac1-camps and Epac1-camps-JNC sensors. 
Representative original traces of YFP and CFP were shown for 1 nM ISO-induced minor 
reaction (Figure 39A, B) and for 10 nM ISO-induced major change in YFP and CFP (Figure 
39D, E).  
The statistical data demonstrated that the change in FRET (% max) significantly increased in 
Epac1-camps-transfected Ctrl-CMs (25.9 ± 1.4), CPVTa-CMs (32.9 ± 1.5), CPVTb-CMs (27.9 ± 
1.6), CPVTc-CMs (26.8 ± 1.2), and CPVT-d-CMs (23.1 ± 1.3) after 10 nM ISO treatment, when 
compared to 1 nM ISO-challenged Ctrl-CMs (9.1 ± 0.9), CPVTa-CMs (12.9 ± 0.8), CPVTb-
CMs (11 ± 1.2), CPVTc-CMs (14 ± 0.9), and CPVTd-CMs (12.2 ± 1.2) (Figure 39C). 
The statistical data also demonstrated that the change in FRET (% max) significantly increased 
in Epac1-camps-JNC-transfected Ctrl-CMs (35.5 ± 1.7), CPVTa-CMs (36.5 ± 1.4), CPVTb-CMs 
(40.45 ± 1.6), CPVTc-CMs (40.1 ± 1.4), and CPVTd-CMs (28.33 ± 1.6) after 10 nM ISO 
treatment, when compared to 1 nM ISO-challenged Ctrl-CMs (24.2 ± 1.6), CPVTa-CMs (22.9 ± 
1.5), CPVTb-CMs (19.9 ± 1.3), CPVTc-CMs (19.3 ± 1.3), and CPVTd-CMs (20.1 ± 1.2) 
(Figure 39F). 
The FRET change in Epac1-camps-expressed CPVTa-CMs (32.97 ± 1.5) was significantly 
higher when compared to Ctrl-CMs (25.91 ± 1.4), indicating that the cytosolic cAMP level was 
higher in CPVTa-CMs than in Ctrl-CMs after 10 nM ISO treatment. Moreover, the FRET change 
in Epac1-camps-JNC-expressed CPVTb- (40.45 ± 1.6) and CPVTc-CMs (40.14 ± 1.5) were 
significantly higher when compared to Ctrl-CMs (35.47 ± 1.7), indicating that the cAMP levels 
at the RYR2 microdomain were higher in these CPVT-CMs than in Ctrl-CMs after 10 nM ISO 
treatment. Interestingly, the FRET change in Epac1-camps-JNC-expressed CPVTd-CMs (28.33 
± 1.6) was significantly lower when compared to Ctrl-CMs (35.47 ± 1.7), indicating that the 
cAMP level at the RYR2 microdomain was lower in CPVTd-CMs than in Ctrl-CMs after 10 nM 







These data indicate that the FRET changes of Epac1-camps- and Epac1-camps-JNC-transfected 
Ctrl-CMs and CPVT-CMs are concentration-dependent for ISO. Therefore, this method can be 
used to predict the activities of different PDEs. 
 
Figure 39. Different FRET changes in Epac1-camps- and Epac1-camps-JNC-transfected CMs 
induced by different ISO concentrations. (A, D) Representatively shown single YFP and CFP intensity 
recordings of the Epac1-camps-transfected CPVTd-CM (A) and Ctrl-CM (D). There was no obvious 
change in CFP (donor) intensity but a slight decrease in YFP (acceptor) intensity when the cell was 
challenging with 1 nM ISO (A). After treated with 10 nM ISO, cAMP caused an increase in CFP intensity 
and a decrease in YFP intensity (D). Change in FRET is shown as a percentage of the maximum change 
after the IBMX treatment to block all PDE activities during the measurement (B, E). For the Epac1-
camps-transfected Ctrl-, CPVTa-, CPVTb-, CPVTc- and CPVTd-CMs, the changes of FRET significantly 
increased in 10 nM ISO when compared to 1 nM, respectively (C). For the Epac1-camps-JNC-transfected 
Ctrl-, CPVTa-, CPVTb-, CPVTc- and CPVTd-CMs, the changes of FRET also significantly increased in 
10 nM ISO when compared to 1nM respectively (F). For these 1 nM and 10 nM ISO-challenged Epac1-
camps-transfected CMs experiments, numbers of Ctrl-, CPVTa-, CPVTb-, CPVTc- and CPVTd-CMs 
equal to 17, 44, 27, 86, 20, 39, 39, 66, 17 and 52, respectively (C, from left to right). For these 1 nM and 
10 nM ISO-challenged Epac1-camps-JNC-transfected CMs experiments, numbers of Ctrl-, CPVTa-, 
CPVTb-, CPVTc- and CPVTd-CMs equal to 17, 38, 30, 88, 15, 36, 37, 66, 14 and 47, respectively (F, 
from left to right). 
 
cAMP production is counterbalanced by hydrolytic activity of PDEs, which can shape a cAMP-
mediated signal after β-adrenergic stimulation. Since PDE2, PDE3, and PDE4 represent the 





PDE4 inhibition to investigate cAMP degradation by different PDE hydrolytic activities in 
Epac1-camps- and Epac1-camps-JNC-transfected Ctrl-CMs and CPVT-CMs. 
 
3.4.2 cAMP degradation by PDE2 hydrolytic activity in iPSC-CMs after β-adrenergic 
stimulation  
 
To monitor the contribution of PDE2 to cAMP degradation, beating iPSC-CMs expressing 
Epac1-camps or Epac1-cams-JNC were challenged with 10 nM ISO first, then with 100 nM Bay 
60-7550 to inhibit PDE2 and last with 100 µM IBMX to block all PDEs. 
To avoid imprecise quantification of PDE contributions, only the percentage of individual PDE 
inhibitor effects, without the ISO portion, from the total PDE inhibition by the unselective 
inhibitor IBMX was quantified. The contribution of PDE2 to cAMP degradation in cytosol after 
β-adrenergic stimulation was significantly higher in Ctrl-CMs (27.56 ± 2.277, n=18) than in 
CPVTa-CMs (15.41 ± 1.143, n=34), CPVTb-CMs (9.48 ± 1.54, n=13), CPVTc-CMs (15.07 ± 
1.419, n=28) and CPVTd-CMs (7.887 ± 1.146, n=16) (Figure 40C). 
 
A                                               B                                          C
 
Figure 40. cAMP-PDE2 activity in cytosol after β-adrenergic stimulation. Beating CMs expressing 
the Epac1-camps were stimulated with ISO (10 nM), following by Bay 60-7550 (100 nM) to block PDE2 
and IBMX (100 µM) to block all PDEs fully. Representative FRET ratio traces were shown for Ctrl-CMs 
(A), and for CPVTb1-CMs (B). (C) PDE2 contribution to cAMP hydrolysis in the bulk cytosol was 
significantly lower in CPVT(a, b, c, d)-CMs when compared to Ctrl-CMs. Data were shown as means ± 






In addition, the contribution of PDE2 to cAMP degradation in the RYR2 compartment after β-
adrenergic stimulation was significantly higher in Ctrl-CMs (39.98 ± 2.461, n=15) than in 
CPVTa-CMs (14.19 ± 1.644, n=26), CPVTb-CMs (25.21 ± 2.78, n=13), CPVTc-CMs (17.32 ± 
1.397, n=25) and CPVTd-CMs (8.606 ± 1.232, n=11) (Figure 41C). 
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Figure 41. cAMP-PDE2 activity in the RYR2 compartment after β-adrenergic stimulation. Beating 
CMs expressing the Epac1-camps-JNC were stimulated with ISO (10 nM), following by Bay 60-7550 
(100 nM) to block PDE2 and IBMX (100 µM) to block all PDEs fully. Representative FRET ratio traces 
were shown for Ctrl-CMs (A), and for CPVTb1-CMs (B). Compared to Ctrl-CMs, CPVT(a, b, c, d)-CMs 
revealed significant lower PDE2 contribution to cAMP hydrolysis in the RYR2 compartment (C). Data 
were shown as means ± SEM. n=15, 26, 13, 25, 11 for Ctrl-, CPVTa-, CPVTb-, CPVTc- and CPVTd-
CMs, respectively. 
 
3.4.3 cAMP degradation by PDE3 hydrolytic activity in iPSC-CMs after β-adrenergic 
stimulation  
 
To monitor the contribution of PDE3 to cAMP degradation, beating iPSC-CMs expressing 
Epac1-camps or Epac1-camps-JNC were challenged with 10 nM ISO first, then with 10 µM 
cilostamide to inhibit PDE3 and last with 100 µM IBMX to block all PDEs. 
Similar to PDE2, the contribution of PDE3 to cAMP degradation in cytosol after β-adrenergic 
stimulation was significantly higher in Ctrl-CMs (35.34 ± 1.911, n=19) than in CPVTa-CMs 
(9.17 ± 1.539, n=23), CPVTb-CMs (15.61 ± 2.639, n=13), CPVTc-CMs (14.7 ± 1.373, n=27) 
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Figure 42. cAMP-PDE3 activity in cytosol after β-adrenergic stimulation. Beating CMs expressing 
the Epac1-camps were stimulated with ISO (10 nM), following by cilostamide (10 µM) to block PDE3 
and IBMX (100 µM) to block all PDEs fully. Representative FRET ratio traces were shown for Ctrl-CMs 
(A), and for CPVTa3-CMs (B). (C) Quantification of FRET responses was shown. CPVT(a, b, c, d)-CMs 
demonstrated a significant lower PDE3 contribution to cAMP hydrolysis in the bulk cytosol compared to 
Ctrl-CMs. Data were shown as means ± SEM. n=19, 23, 13, 27 and 18 for Ctrl-, CPVTa-, CPVTb-, 
CPVTc- and CPVTd-CMs, respectively. 
 
The contribution of PDE3 to cAMP degradation in the RYR2 compartment after β-adrenergic 
stimulation was also significantly higher in Ctrl-CMs (49.84 ± 2.469, n=17) than in CPVTa-CMs 
(16.31 ± 1.988, n=30), CPVTb-CMs (21.13 ± 3.241, n=11), CPVTc-CMs (20.31 ± 2.592, n=25) 
and CPVTd-CMs (8.163 ± 1.329, n=16) (Figure 43C). 
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Figure 43. cAMP-PDE3 activity in the RYR2 compartment after β-adrenergic stimulation Beating 
CMs expressing the Epac1-camps-JNC were stimulated with ISO (10 nM), following cilostamide (10 
µM) to block PDE3 and IBMX (100 µM) to block all PDEs fully. Representative FRET ratio traces were 
shown for Ctrl- (A), and for CPVTc1-CMs (B). Compared to Ctrl-CMs, CPVT(a, b, c, d)-CMs showed 






3.4.4 cAMP degradation by PDE4 hydrolytic activity in iPSC-CMs after β-adrenergic 
stimulation  
 
Pilot experiments showed that stimulation with 10 nM ISO led to an increase in cAMP, and 
addition of the PDE4 inhibitor rolipram further raised cAMP concentration to levels that were 
high enough to saturate the FRET sensors (data not shown). To measure the dynamic range of 
the FRET sensors, PDE4 inhibition was performed upon stimulation with 1 nM ISO, which can 
induce smaller changes in cAMP concentration than 10 nM in all iPSC-CMs no matter in cytosol 
or at the RYR2 compartment (Figure 39), allowing visualization of the complete FRET response 
to rolipram. 
Different from PDE2 and PDE3 activities in CPVT-CMs, the contribution of PDE4 to cAMP 
degradation in cytosol after 1 nM ISO stimulation was significantly lower in CPVTb-CMs (36.5 
± 4.77, n=20) and CPVTc-CMs (45.67 ± 4.108, n=39), when compared to Ctrl-CMs (71.72 ± 
3.749, n=17). This was not the case for CPVTa-CMs (74.23 ± 2.378, n=27) and CPVTd-CMs 
(66.05 ± 3.94, n=14)  (Figure 44D). 







Figure 44. cAMP-PDE4 activity in cytosol after β-adrenergic stimulation. Beating CMs expressing 
the Epac1-camps were stimulated with ISO (1 nM), following by rolipram (10 µM) to block PDE4 and 
IBMX (100 µM) to block all PDEs fully. Representative FRET ratio traces were shown for Ctrl-CMs (A), 
CPVTb1-CMs (B) and CPVTa3-CMs (C). (D) Quantification of FRET responses was shown. CPVTb- 
and CPVTc-CMs revealed a significant lower PDE4 contribution to cAMP hydrolysis in the bulk cytosol 
compared to Ctrl-CMs. Data were shown as means ± SEM. n=17, 27, 20, 39 and 14 for Ctrl-, CPVTa-, 
CPVTb-, CPVTc- and CPVTd-CMs, respectively. 
 
Interestingly, the PDE4 contribution to cAMP degradation at the RYR2 compartment in CPVTc-
CMs (55.92 ± 4.379, n=37) and CPVTd-CMs (34.26 ± 4.865, n=12) was significantly lower, but 
not in CPVTa-CMs (82.05 ± 1.97, n=30) and CPVTb-CMs (73.16 ± 5.574, n=15), when 






Figure 45. cAMP-PDE4 activity in the RYR2 compartment after β-adrenergic stimulation. Beating 
CMs expressing the Epac1-camps-JNC were stimulated with ISO (1 nM), following by rolipram (10 µM) 
to block PDE4 and IBMX (100 µM) to block all PDEs fully. Representative FRET ratio traces were 
shown for Ctrl-CMs (A), CPVTa3-CMs (B) and CPVTd1-CMs (C). (D) Quantification of FRET 
responses was shown. CPVT(c, d)-CMs exhibited a significant lower PDE4 contribution to cAMP 
hydrolysis in the RYR2 compartment compared to Ctrl-CMs. Data were shown as means ± SEM. n=17, 







CPVT is characterized by abnormal calcium handling, ventricular arrhythmias, and sudden 
cardiac death induced by exercise or acute emotion in individuals without structural cardiac 
abnormalities. The overwhelming majority (more than 76%) of the identified RYR2 mutations 
(more than 150) were classified in clusters in four distinct regions. However, the underlying 
electrophysiological mechanisms have not been completely understood. Patient-specific hiPSCs 
as a renewable and reliable source for CMs provide the possibility to study the pathophysiology 
of genetic diseases in vitro.  
The aim of this thesis was to investigate whether CMs differentiated from hiPSCs generated 
from CPVT patients could recapitulate electrophysiological features of the disease in vitro as 
well as to test the effect of antiarrhythmic drugs on the function of CPVT-iPSC-CMs. In addition, 
the cAMP dynamic was investigated. 
Somatic cells from skin biopsies of CPVT patients carrying the RYR2 mutation in domain a 
(R420W), domain b (A2254V), domain c (E4076K) or domain d (H4742Y) were isolated and 
reprogrammed into patient-specific iPSCs. The generated Ctrl- and CPVT-iPSCs exhibited 
hESC-like characteristics, demonstrated by pluripotency-related gene expression, in vitro 
differentiation capacity, and teratoma formation in vivo. Furthermore, both Ctrl- and CPVT-
hiPSCs were able to differentiate into functional CMs, which were shown by spontaneous 
contraction and cardiac-specific protein expression. 
Electrophysiological analyses showed that the CPVT-CMs recapitulated the phenotype of CPVT 
both by patch-clamp assessment and by MEA assessment. The single CPVTd-CMs showed a 
unique EAD phenotype in basal condition and ISO-challenged condition whereas CPVTa-, 
CPVTb- and CPVTc-iPSC-CMs exhibited DADs and DAD-induced TAs, which were 
significantly enhanced after the ISO treatment. In the monolayer cultures, all CPVT-CMs 
revealed a significantly increased number of PVC- and VT-like events after the ISO treatment. In 
contrast, no increased appearance of DADs, EADs, DAD- or EAD-induced TAs, and PVC- and 
VT-like events was observed in Ctrl-iPSC-CMs after the ISO treatment. The stress-induced 
arrhythmia can be specifically alleviated by the treatment with four different therapeutic drugs 





The activities of PDE2 and PDE3 in all CPVT(a, b, c, d)-CMs were lower than in Ctrl-CMs no 
matter in cytosol or at the RYR2 compartment through FRET measurement. However, for PDE4, 
there was a lower activity in cytosol in CPVTb- and CPVTc-iPSC-CMs when compared to Ctrl-
iPSC-CMs, and a lower activity at the RYR2 compartment in CPVTc- and CPVTd-iPSC-CMs 
when compared to Ctrl-iPSC-CMs.  
 
4.1 Generation and characterization of hiPSCs and iPSC-CMs differentiation 
 
It has been ten years since Shinya Yamanaka published his milestone work for cell 
reprogramming (Takahashi and Yamanaka, 2006). To address the safety issues arisen from 
harboring integrated exogenous sequences in the target cell genome, a number of methods have 
been developed to produce iPSCs with potentially reduced risks, which included non-
integrational adenoviral (Stadtfeld et al., 2008; Zhou and Freed, 2009), non-integrational Sendai 
viral (Fujie et al., 2014; Fusaki et al., 2009), synthetic mRNA (Warren et al., 2010; Yakubov et 
al., 2010) and cell-penetrating protein reprogramming (Kim et al., 2009; Zhou et al., 2009). The 
Ding’s group showed that somatic cells can be reprogrammed by combining OCT4 and KLF4 
with small-molecule compounds (Shi et al., 2008) to improve induction of human iPSCs through 
chemical compound treatment (Lin et al., 2009), and by using recombinant proteins (Zhou et al., 
2009). Finally, a group led by Hongkui Deng reported that they were able to get 0.2% of cells to 
convert to iPSCs (results comparable to those from standard virus iPSC production techniques) 
by using a cocktail of seven compounds (Hou et al., 2013).  
In this study, the Sendai virus system containing the four Yamanaka factors OCT4, SOX2, KLF4, 
and C-MYC was used for the reprogramming of fibroblasts from healthy donors and CPVT 
patents into transgene-free hiPSCs. The Sendai virus system enables RNA-based gene delivery 
of pluripotency-associated factors and shows a high efficiency (Fujie et al., 2014; Fusaki et al., 
2009).  
The hiPSCs generated in the present study showed typical hiPSC-like characteristics with 
regards to their morphology, expression of pluripotency-related marker genes, including OCT4, 





pluripotency-related factors at protein level, including NANOG, OCT4, SOX2, LIN28, SSEA4 
and TRA1-60 (Figure 13). 
Furthermore, CPVTa2, CPVTa3 and CPVTd1 iPSCs expressed markers specific for all three 
germ layers upon in vitro differentiation, demonstrating that they are truly pluripotent. The 
ability to differentiate into almost all tissue types is the hallmark of human pluripotent stem cells 
(Itskovitz-Eldor et al., 2000). Gene expression analyses demonstrated the expression of germ 
layer-specific markers AFP, ALB, α-MHC, cTNT, SYP and TH on RNA level, indicating the 
ability of CPVT(a2, a3, d1)-iPSCs to differentiate into the all three germ layers (endodermal, 
mesodermal, and ectodermal lineages) (Figure 14). Protein expression analyses indicated the 
expression of germ layer-specific markers AFP, SMA and βIII-tubulin on protein level, making 
sure the ability of CPVT(a2, a3, d1)-iPSCs to differentiate into derivatives of all three germ 
layers (endodermal, mesodermal, and ectodermal lineages) (Figure 15). Apart from in vitro 
differentiation experiments, teratoma formation assays are the “gold standard” for demonstrating 
the differentiation potential of human pluripotent stem cells (Buta et al., 2013; Hentze et al., 
2009). In vivo differentiation of CPVT(a2, a3, d1)-iPSCs (Figure 16) revealed tissue-specific 
cells, including derivatives of all three germ layers, such as intestinal tissue (endoderm), cartilage 
and muscle cells (mesoderm) and neural rosettes (ectoderm).  
Furthermore, sequencing analyses confirm that CPVTa2 and a3-hiPSCs carry a missense single 
nucleotide polymorphism on position 1258, with a cytosine on the one allele and a thymine on 
the other. The variant leads to a codon for tryptophan (R420W). Sequencing analyses also 
conform that CPVTd1-hiPSCs contain a missense single nucleotide polymorphism on position 
14224, with a cytosine on the one allele and a thymine on the other. This variant leads to a codon 
for tyrosine (H4742Y) (Figure 18). 
Taken together, the generated patient-specific hiPSCs have similar characteristics of human 
pluripotent stem cells as previously reported and fulfill the criteria defining fully reprogrammed 
hiPSCs with a stable karyotype. Because of their origin (somatic cells), their further use for 
research purposes does not raise ethical concerns as human embryonic stem cells do. 
 
To establish a disease modeling system from CPVT patients, generation of patient-specific 





functional CMs by defined factors was materialized by Ieda et al.  (Ieda et al., 2010). Zhang et al. 
recently reported that the expandable cardiovascular progenitor cells reprogrammed from 
fibroblasts were a powerful system to use as heart disease model and to provide strategies for 
regenerative medicine in the heart (Zhang et al., 2016). The strategy of direct convention of 
fibroblasts into functional CMs by small molecules bypass the pluripotency stage (Cao et al., 
2016) provides a new cost- and time-effective way to perform cardiovascular disease modeling 
and therapeutic implications, even though there is no corresponding literature published 
nowadays. 
In the present study, directed cardiac differentiation methods are used for the generation of 
functional CMs. To produce sufficient CMs for in vitro analyses, upscaling generation of CMs 
from hiPSCs is essential. In this study, the directed cardiac differentiation method (Lian et al., 
2012; Lian et al., 2013) is combined with a mechanical selection (removal of non-cardiac 
clusters) for the generation of CMs in large quantities and with a high purity (> 80%). Although 
the lactate replacement method is widely used for CM selection (Tohyama et al., 2013), side 
effects such as an altered expression profile and maturation due to metabolic selection are still 
not clearly investigated. Immunofluorescence staining demonstrated that hiPSC-derived CMs 
expressed sarcomeric and gap junction proteins Cx43, which are critical for cardiac function. 
This study shows a cardiac-specific protein expression in CPVT(a2, a3, d1)-CMs similar to Ctrl-
CMs, represented by cTNT, MLC2a, MLC2v, α-actinin, and Cx43 staining. This is consistent 
with the clinical findings that patients diagnosed with CPVT have a structurally normal heart 
(Lieve et al., 2016). 
Electrophysiological recordings in both Ctrl- and CPVT-CMs reveal, on the basis of distinct 
classes of APs, the three major cardiac subtypes: embryonic ventricular-, atrial-, and nodal-like 
CMs, similar to those found in hiPSC-derived CMs (Jung et al., 2012). This classification is 
based on the shape and properties of the APs, such as the RMP, APA, Vmax, and prominence of a 
plateau phase. Using the directed cardiac differentiation protocol, the majority of the cardiac 
subtype is ventricular-like with typical AP characteristics (Figure 22), consistent with the 
immunostaining results showing that majority of CMs are MLC2v positive (Figure 20). During 
the development of the human heart, MLC2v is exclusively expressed in ventricular CMs (Chuva 





Therefore, ventricular CMs derived from patient-specific hiPSCs carrying the mutations by using 
the directed cardiac differentiation method are suitable for CPVT disease modeling. 
 
4.2 CPVT-CMs can recapitulate electrophysiological phenotypes and imply distinguish 
pathologies 
 
Since RYR2 is a very large gene, it is not possible until now to exogenously introduce the RYR2 
mutations into adult CMs to assess the resulting consequences of genetic modifications in RYR2 
in vitro. Most studies of the pathophysiological mechanisms are conducted in cellular 
heterologous overexpression studies or in knock-in mouse models (Medeiros-Domingo et al., 
2009; Priori and Chen, 2011). Until now, only a few mutations (about 15%) have been 
investigated in heterologous overexpression studies or knock-in mouse models (Kashimura et al., 
2010; Sedej et al., 2010; Zhang et al., 2013b). The different results from the previous studies 
make it difficult to elucidate the underlying mechanisms of calcium leak from different RYR2 
mutations. Although heterologous expression systems and animal models (Lehnart et al., 2008) 
have shown important insights into the CPVT pathogenesis, the lack of in vitro sources for 
human CMs and the inability to model patient-specific variations of the disease significantly 
impedes the investigation of this disease. Therefore, further investigations using patient-specific 
cells are necessary. The new technology of iPSCs allows us to study human cardiovascular 
diseases using patient-specific cells in vitro (Itzhaki et al., 2012). 
Since ECG is broadly used to quantify arrhythmic events in murine CPVT mouse models 
(Cerrone et al., 2005; Cerrone et al., 2007; Kannankeril et al., 2006; Kobayashi et al., 2010; 
Lehnart et al., 2008; Song et al., 2007), the corresponding method to assess arrhythmia in iPSC-
CM models for CPVT is still lacking. The MEA technology seems to be a standard procedure 
widely used for modeling of long QT syndrome using iPSC-CMs (Egashira et al., 2012; 
Friedrichs et al., 2015; Itzhaki et al., 2011; Lahti et al., 2012; Matsa et al., 2011), due to non-
invasive measurements of local field potential duration (or QT interval) representing the AP 
duration. However, for CPVT modeling, the MEA system was only used to analyze an activation 
map, beating frequency and variation in beat period and corrected field potential duration by 
using iPSC-CM aggregates but not monolayer (Itzhaki et al., 2012; Preininger et al., 2016). 





it hard to analyze arrhythmic events included PVC-like events and PVC-like-induced VT-like 
events (Figure 26). 
This is the first study to present PVC-like and VT-like events in CMs derived from CPVT-iPSCs 
by using the MEA technology. The non-sustained ventricular arrhythmia are very common in 
ECG recording (Curtis et al., 2013), but rare in this study. Sinoatrial node has the potential to 
correct the abnormal electrical activities of ventricle in the heart. However, there is no stronger 
enough sinus rhythm generated in the monolayer of MEA recording to correct PVC-like events. 
Therefore, the PVC-like events will evolve into VT-like events but not into non-sustained 
ventricular tachycardia. 
Traditionally, the mechanisms for CPVT arrhythmogenesis required RYR2 affected by the gain-
of-function mutations (Blayney and Lai, 2009; Kontula et al., 2005; Liu et al., 2009; Marks, 
2013; Priori and Chen, 2011; Priori and Napolitano, 2005; Sumitomo, 2015; Wehrens and Marks, 
2003). Premature spontaneous SR Ca2+ release or Ca2+ spillover occurs under conditions of SR 
Ca2+ overload caused by stress. The resulting spontaneous Ca2+ elevation during diastole 
activates the sodium-calcium exchanger, which in turn depolarizes the cell membrane and 
generates DADs. DADs of sufficient amplitude then trigger APs, which give rise to the typical 
polymorphic VT in CPVT. However, this traditional mechanism is challenged by several other 
mechanisms (Liu et al., 2009; Zhao et al., 2015).  
In this study, iPSC-CMs from six CPVT patients with four different mutations at four different 
domains (a-d) of RYR2 were investigated. The CPVTa2 and CPVTa3 iPSC lines are generated 
from patients harboring heterozygous mutation (R420W), which is located in the N-terminal 
domain (residues 1-642) (Figure 4). Cases with the R420W mutation have been reported to 
show arrhythmogenic right ventricular cardiomyopathy-like phenotypes of mild fatty infiltration 
in the heart apex (Nishio et al., 2006) despite the notion that patients with RYR2 mutations show 
structurally normal hearts. Different results using a knock-in mouse model of the Ryr2 mutation 
R420W were reported. One study showed that hypertrophy of lymphoid organs was a possible 
phenotypic characteristic of Ryr2 R420W mutation whereas the heart weight was not changed 
(Nishio et al., 2014). The other study emphasized that histology of the heart did not detect any 
differences between the homozygous and wild-type mice (Okudaira et al., 2014). However, the 





Ca2+ transient amplitude was decreased in Ryr2R420W/R420W knock-in mouse model. Nevertheless, 
the point mutation R420Q causing CPVT phenotype behaves as a gain-of-function both in 
permeabilized and intact cells (Domingo et al., 2015). The complex mechanism of mutation 
R420Q goes deeper into structure level these years (Borko et al., 2014; Kimlicka et al., 2013). 
The RYR2 R420Q mutation has been observed ablating chloride binding, and disturbing its 
domain folding in the crystal structure of the N-terminal region (Borko et al., 2014; Kimlicka et 
al., 2013). It appears clear that the R420Q mutation destabilizes the inter-subunit interface, 
probably facilitating the channel opening. Recently, a CPVT-iPSC-CMs model was used to study 
the RYR2R420Q mutation compared with CASQ2D307H mutation, revealing several calcium 
handling abnormalities (Novak et al., 2015). In this study, patient-specific iPSC-CMs with the 
RYR2 mutation R420W, which has not been studied before in iPSC models, showed the lower 
beating frequency when compared to Ctrl-CMs after the ISO treatment as well as the increased 
number of DADs, DAD-induced TAs and PVC-like or VT-like events. These findings are in line 
with the data showing bradycardia, irregularity in RR intervals and increased VT-like events in 
Ryr2R420W/R420W knock-in mouse model after β-adrenergic stimulation (Okudaira et al., 2014). 
Furthermore, in our lab, we could show that ISO stimulation of fluo 4/AM-loaded CPVTa-CMs 
(R420W) leads to increased spontaneous Ca2+ release determined by Ca2+ spark analysis using 
confocal line scanning technique (L. Cyganek, unpublished data). However, when compared to 
Ctrl-CMs, the frequency of Ca2+ sparks in CPVTa-CMs after the ISO treatment is lower. Future 
study should focus on the abnormality of Ca2+ transients to better understand the underlying 
mechanism for RYR2R420W-caused CPVT. 
Although some literatures reported that the RYR2A2254V mutation is correlated with the clinical 
outcome of CPVT patients (Medeiros-Domingo et al., 2009; Postma et al., 2005; van der Werf et 
al., 2012a), investigation of its underlying mechanism has not been reported. Based on the latest 
structure analysis of porcine Ryr2 using the cryo-electron microscopy (Peng et al., 2016), A2254 
residue is located in the helical domain 1 (residues 2111-2679) (Figure 4). The structure analysis 
of the rabbit Ryr1 in complex with its modulator FKBP12 by using single-particle electron cryo-
microscopy demonstrates that FKBP12 is bound in a cleft formed by the handle, N-terminal and 
SPRY1/3 domains (Yan et al., 2015). Crystal structures of Ryr2 reveal that the hydrophobic 
cluster within SPRY1 is crucial for FKBP binding (Yuchi et al., 2015). In this study, patient-





iPSC models or in mouse knock-in models, showed the increased number of DADs, DAD-
induced TAs and PVC-like or VT-like events when compared to Ctrl-CMs after the ISO 
treatment. The beating frequency in CPVTb-CMs is comparable with that in Ctrl-CMs. 
Furthermore, in our lab, we could show that ISO stimulation of fluo 4/AM-loaded CPVTb-CMs 
(A2254V) leads to increased spontaneous Ca2+ release determined by Ca2+ spark analysis using 
confocal line scanning technique (L. Cyganek, unpublished data). When compared to Ctrl-CMs, 
the frequency of Ca2+ sparks in CPVTb-CMs after the ISO treatment is significantly higher. 
These findings suggest that RYR2A2254V is a gain-of-function mutation. Future study should 
figure out whether the FKBP12 binding is changed in CPVTb-CMs. 
Similar to RYR2A2254V, the underlying mechanism of CPVT caused by the RYR2E4076K mutation 
has not been studied, although there are some literatures reporting its clinical relevance 
(Medeiros-Domingo et al., 2009; Postma et al., 2005; van der Werf et al., 2012a). E4076K 
mutation is located in the central domain of RYR2 (residues 3613-4207) (Figure 4). In addition, 
Xiong et al. have identified two helix-loop-helix structural (EF-hand) Ca2+ binding motifs in 
Ryr2 (residues 4036-4082) (Xiong et al., 1998). The residue E4076 is participating in the 
formation of the second EF-hand motif. Deleting the entire EF-hand motif in the central domain 
does not affect cytosolic Ca2+ activation of single RYR2 channels, suggesting that the EF-hand is 
unlikely to be the cytosolic Ca2+ sensor (Guo et al., 2016). Atomic-resolution structures of Ryr2 
may unveil the Ca2+ binding sites in the central domain for cytosolic Ca2+ activation (Peng et al., 
2016). Nevertheless, the EF-hand Ca2+ binding domain is important for luminal Ca2+ activation 
of Ryr2 and for the activation and termination of store overload-triggered Ca2+ release (Guo et 
al., 2016). 
In this study, patient-specific iPSC-CMs with the RYR2 mutation E4076K, which has not been 
studied before either in iPSC models or in mouse knock-in models, showed the increased number 
of DADs, DAD-induced TAs and PVC-like or VT-like events when compared to Ctrl-CMs after 
the ISO treatment. The beating frequency in CPVTc-CMs is comparable with that in Ctrl-CMs. 
Furthermore, ISO stimulation of CPVTc-CMs (E4076K) leads to increased spontaneous Ca2+ 
release (L. Cyganek, unpublished data). When compared to Ctrl-CMs, the frequency of Ca2+ 
sparks in CPVTc-CMs after the ISO treatment is significantly higher. These findings suggest that 





on cytosolic and luminal Ca2+ activation as well as the activation and termination of store 
overload-triggered Ca2+ release in CPVTc-CMs. 
By combining calcium sensitivity testing with single channel recordings and [3H]ryanodine 
binding technologies in human embryonic kidney 293 cells or HL-1 CMs overexpressed with 
Ryr2 heterozygous mutations, the Chen’s group has dedicated to investigating of Ryr2 function 
for several decades. The SOICR mechanism is suggested as a universal mechanism for 
explaining CPVT pathology. Despite contentious results reported, the highly conserved luminal 
Ca2+-sensing RYR2 residue E4872, which is located in the transmembrane domain, was 
identified (Chen et al., 2014). The Chen’s group found a novel mutant RYR2A4860G, which can 
result in the loss of luminal Ca2+ activation in Ryr2 and is associated with ventricular fibrillation 
and sudden death (Jiang et al., 2007). Furthermore, in 2015, Zhao et al. reported a novel loss-of-
function mechanism to explain lethal arrhythmia in mice harboring CPVT-linked Ryr2 mutation 
A4860G (Zhao et al., 2015). They showed that the Ryr2 channel activity was dramatically 
inhibited, as inferred by [3H]ryanodine binding and single channel recordings.  
The mutation RYR2H4742Y studied in this study has never been investigated before, which is 
located in the S4 transmembrane segment of the RYR2 channel (residues 4486-4968) (Figure 4), 
referring to the latest Ryr2 structure. All the S6 segment mutations D4868A, E4872A, R4874A, 
and E4878A, which were reported previously, showed loss-of-function properties such as 
decreasing caffeine sensitivities (Peng et al., 2016). Furthermore, suppression of Ryr2 function 
has been reported recently (Zhong et al., 2016), using a unique mouse model harboring a 
Rry2E4872Q mutation. A novel RYR2 loss-of-function mutation (I4855M) associated with left 
ventricular non-compaction and atypical CPVT has also been reported (Roston et al., 2016). 
In this study, the beating frequency in CPVTd-CMs with RYR2H4742Y is significantly lower than 
in Ctrl-CMs. These data are in line with the findings showing that mice heterozygous for the 
Ryr2A4860G mutation (Ryr2-A4860G+/−), which is a loss-of-function mutation, exhibited basal 
bradycardia (Zhao et al., 2015). In ISO-stimulated ventricular CMs, the Ryr2A4860G mutation 
decreased the peak of Ca2+ release during systole, gradually overloading the SR with Ca2+. The 
resultant Ca2+ overload then randomly caused bursts of prolonged Ca2+ release, activating 
electrogenic Na+-Ca2+exchanger activity and triggering EADs (Zhao et al., 2015). In this study, 





induced TAs and PVC-like or VT-like events when compared to Ctrl-CMs. It is interesting to 
observe that the arrhythmic parameters in CPVTd-CMs (number of DADs and TAs, number of 
EADs and TAs) did not change significantly, but the percentage of arrhythmic cells increased 
after 100 nM ISO treatment. Furthermore, ISO stimulation of CPVTd-CMs (RYR2H4742Y) leads 
to increased spontaneous Ca2+ release (L. Cyganek, unpublished data), however, when compared 
to Ctrl-CMs, the frequency of Ca2+ sparks in CPVTd-CMs after the ISO treatment is significantly 
lower. These findings suggest that H4742Y is a loss-of-function mutation. Further studies should 
be performed to analyze cytosolic and luminal calcium sensitivity, calcium store and caffeine 
sensitivity in CPVTd-CMs. This is the first study to widen the loss-of-function of RYR2 
mutations to the S4 segment of the transmembrane domain. 
Based on the advantages of patient-specific iPSC-CMs, it is possible to systematically compare 
CPVT(a, b, c, d)-CMs harboring RYR2 mutations R420W, A2254V, E4076K, and H4742Y, 
respectively, with Ctrl-CMs in non-ISO-treated or ISO-challenged conditions. The results 
showed in this study strongly imply mutation-specific mechanisms in CPVT pathology.  
In the non-ISO-stimulated and ISO-stimulated conditions, the beating frequencies of CPVTa-
CMs and CPVTd-CMs are significantly lower than Ctrl-CMs (Figure 24, Figure 27). This is 
probably due to the prolonged APDs in CPVTa-CMs and CPVTd-CMs when compared to Ctrl-
CMs (Figure 23). 
All the beating frequencies in Ctrl-CMs and CPVT(a, b, c, d)-CMs increased after 100 nM ISO 
stimulation as assessed by MEA recording (Figure 30B), while the beating frequencies by patch-
clamp recording showed a more complex profile (Figure 29B). The reasonable explanation is 
that the frequencies in MEA recordings were calculated from the sinus rhythm electrode, which 
did not have arrhythmic events (every culture has nine-electrode recordings). However, for 
patch-clamp recording, the beating frequencies are quantified by AP traces, which contained 
many arrhythmic events: DADs, EADs, and DADs- or EADs- induced TAs. The not-increased 
beating frequency in CPVTb- and CPVTc-CMs after the ISO treatment is due to the strongly 
induced irregular beating, including the stopped beating. 
After 100 nM ISO treatment, the parameters assessing the arrhythmic severity degrees, including 
the percentage of arrhythmic single cells, the percentage of arrhythmic monolayer cultures, 





events were significantly higher in CPVT(a, b, c)-CMs not only in comparison to ISO-
challenged Ctrl-CMs but also to their corresponding non-ISO-treated conditions. These results 
are consistent with previous findings using iPSCs from CPVT patients harboring RYR2 
mutations Glu2311Asp (Di Pasquale et al., 2013), F2483I (Fatima et al., 2011b), M4109R 
(Itzhaki et al., 2012), S406L (Jung et al., 2012), and P2328S (Kujala et al., 2012). 
Taken together, the electrophysiological and calcium handling studies demonstrate that iPSC-
CMs not only can recapitulate CPVT phenotype (DADs, EADs, and TAs in patch-clamp 
experiments, PVC-like and VT-like events in MEA recording, and altered calcium handling) but 
also can be used to investigate mutation-specific arrhythmogenesis or to test drugs. 
 
4.3 Drug testing using CPVT-CMs 
 
With the advent of iPSC technology, they have become a wonderful tool for modeling and 
investigating human diseases, for testing new drugs as well as for testing candidate drugs for 
their cardiotoxicity (Matsa et al., 2014). 
Recently, lots of novel and fashionable methods are invented to carry out drug testing or 
screening, four of which are methods of integrated video microscopy and image analysis 
software platform to characterize the beating of iPSC-CMs (Maddah et al., 2015), methods using 
genetically encoded voltage and calcium fluorescent indicators (Shinnawi et al., 2015), methods 
combining machine learning paired with brightfield optical flow to automate the detection of CM 
drug effects (Lee et al., 2015) and methods virally introducing optogenetic drivers high-
throughput all-optical dynamic cardiac electrophysiology (Klimas et al., 2016). 
Electrophysiological assessments with patch-clamp and MEA techniques are still golden 
standard although patch-clamp analysis requires manual operation by a trained 
electrophysiologist and inherently low-throughput will not be suitable for large-scale drug testing. 
Liang et al. recently applied whole-cell patch-clamp technique to investigate APD and drug-
induced arrhythmia and recapitulated drug-induced cardiotoxicity profiles for healthy subjects 
and patients with long QT syndrome, HCM, and DCM by using disease-specific hiPSC-CMs 





Currently, β-blockers are the basis of antiarrhythmic therapy for CPVT patients (Napolitano et 
al., 1993). However, for unknown reasons, β-blockers are unsuccessful in eliminating stress-
induced ventricular arrhythmias in approximately 25% of CPVT patients (Preininger et al., 2016; 
Roston et al., 2015). Two kinds of clinical surgeries, ICD and left cardiac sympathetic 
denervation, have many drawbacks. Moreover, some antiarrhythmic drugs (e.g., quinidine, and  
verapamil), which typically target plasma membrane ion channels, have limited clinical success 
and in some cases, have been described as being pro-arrhythmic (McCauley and Wehrens, 2011). 
The pathological release of Ca2+ from the SR through RYR2 could represent a promising target 
for antiarrhythmic therapy. In this study, four of antiarrhythmic agents (flecainide, dantrolene, 
rycal1 and rycal2), which mainly target RYR2, are recruited to assess their antiarrhythmic 
efficacy in CPVT-iPSC-CMs. 
In this study, the evaluation of arrhythmic events in Ctrl-CMs and CPVT(a, b, c, d)-CMs in both 
non-ISO-challenged and ISO-stimulated condition by patch-clamp and MEA techniques 
demonstrates that CPVT-iPSC-CMs provide a reliable platform for testing of antiarrhythmic 
drugs and that patch-clamp and MEA techniques are suitable for studying the effect of the drugs 
on the function of the diseased CMs. 
 
4.3.1 Two clinical drugs (flecainide and dantrolene) show their antiarrhythmic effects on 
CPVT(a, b, c)-CMs but not on CPVTd-CMs 
 
Flecainide is a trifluoroethoxybenzamide that was discovered to be a potent antiarrhythmic agent 
(McCauley and Wehrens, 2011). The mechanism of therapeutic efficacy of flecainide for CPVT 
is unclear. Flecainide has a known sodium channel blocking effect (Watanabe et al., 2009). 
However, Yang et al. recently demonstrated that the effects of flecainide on the Na+ channel are 
insufficient to explain its efficacy in CPVT (Yang et al., 2016). On the other hand, the 
mechanism suggesting inhibitions of Ryr2 by flecainide (Hilliard et al., 2010; Watanabe et al., 
2009) is becoming controversial (Bannister et al., 2015). 
Watanabe et al. reported that flecainide prevents CPVT in mice by decreasing Ryr2 opening 
probability (Watanabe et al., 2009). The authors also indicated that flecainide completely 





drug therapy. Liu et al. demonstrated that flecainide had an antiarrhythmic effect in a CPVT 
mouse Ryr2R4496C model by increasing the threshold for triggered activity through its sodium 
channel blocking effect (Liu et al., 2011). In recent years, Itzhaki et al. showed that flecainide 
completely eliminated or significantly decreased afterdepolarizations and triggered activities in 
patient-specific CPVT (M4109R) -hiPSCs-CMs (Itzhaki et al., 2012).  
In this study, systematic comparison of the antiarrhythmic efficacy of flecainide in CPVT-CMs 
with different mutation-specific mutations in RYR2 was performed for the first time. 
Flecainide showed antiarrhythmic effects on CPVT(a, b, c)-CMs harboring RYR2 mutations 
R420W, A2254V, and E4076K, demonstrated by electrophysiological results (Figure 31, Figure 
32). These findings are consistent with the previously published data using iPSC-CMs from a 
CPVT patient carrying the RYR2M4109R mutation (Itzhaki et al., 2012), which is located in the 
central domain (residues 3613-4207) of RYR2. However, flecainide had no antiarrhythmic effect 
on CPVTd-CMs with the RYR2H4742Y mutation, and even a slightly increased number of EADs 
or EAD-induced TAs was observed in CPVTd-CMs after treatment with flecainide. It is 
evidently suggesting that physicians should consider the CPVT patients’ genetic background 
when flecainide is planned for clinical treatment of the disease. 
Dantrolene is a specific agent for the treatment of malignant hyperthermia. It is known that 
dantrolene can inhibit Ca2+ leak by correcting the defective inter-domain interaction between N-
terminal (1–619 amino acid) and central (2,000–2,500 amino acid) domains of RYRs (both 
RYR1 and RYR2) (Kobayashi et al., 2009). Dantrolene has been shown to improve intracellular 
Ca2+ handling in failing CMs from a canine model of heart failure and prevent arrhythmias in a 
knock-in Ryr2R2474S mouse model of CPVT (Kobayashi et al., 2009). It has been demonstrated 
that superfusion of CPVT (S406L) hiPSCs-CMs with 10 µM dantrolene could prevent the 
appearance of arrhythmia (Jung et al., 2012).  
Dantrolene reduce the number of PVCs on average of 74% (range 33-97) in four patients with N-
terminal or central mutations in the cytosolic region of the RYR2 protein, while dantrolene had 
no effect in two patients with mutations in Q4201R or near the transmembrane domain (V4653F) 
(Penttinen et al., 2015). This was the first publication to show some clues for different 





however only one drug (dantrolene) was investigated for its antiarrhythmic effect on various 
RYR2 mutations. 
In this study, dantrolene showed antiarrhythmic effects on CPVT(a, b, c)-CMs harboring RYR2 
mutations R420W, A2254V and E4076K but not on CPVTd-CMs with the RYR2 mutation 
H4742Y, shown by electrophysiology results (Figure 33, Figure 34), which is consistent with 
the data from Penttinen et al. (Penttinen et al., 2015). 
Future studies should focus on the mechanisms how flecainide and dantrolene affect the function 
of CPVT-CMs.  
 
4.3.2 Two experimental RYR2 stabilizers (rycal1 and rycal2) show their antiarrhythmic 
effects on CPVT(a, b, c)-CMs but not on CPVTd-CMs 
 
The classic fight-or-flight stress response involves activation of the sympathetic nervous system 
and release of catecholamines that bind to β-ARs and raise the second messenger cAMP levels, 
which activates PKA (Eschenhagen, 2010). PKA activates RYR2, the LTCC and the calcium 
uptake pathway through the calcium pump. When PKA phosphorylates RYR2 in the heart, 
calstabin2 is dissociated, increasing the activity of the channel (Brillantes et al., 1994; Jayaraman 
et al., 1992; Marx et al., 2000; Wehrens et al., 2003). 
In 1994, The Marks’s group reported that Ryr expressed without calstabin in insects resulted in 
hyperactive leaky calcium channels, nevertheless, the channel was stabilized and the leak was 
“fixed” when Ryr was co-expressed with calstabin (Brillantes et al., 1994). Calstabin2 deficiency 
is a critical mediator of triggers that initiate cardiac arrhythmias, which were confirmed in 
calstabin2-deficient mice and with enhancing calstabin2 binding to Ryrs by JTV519 (1,4-
benzothiazepinea) (Lehnart et al., 2006; Wehrens et al., 2005; Wehrens et al., 2004b). JTV519 
was designed as one of the rycals, which are small-molecule therapeutic drugs developed first in 
the laboratory of Dr. Andrew R. Marks at Columbia University in New York, which inhibit the 
Ryr2 leak by enhancing calstabin2 binding to the RYR2 channel and stabilizing its closed state 
(Wehrens et al., 2004b). JTV519 can effectively reduce arrhythmic events triggered by elevation 
of SR Ca2+ load of murine ventricular myocytes harboring a human RYR2R4496C+/- mutation 





completely normalized the gain-of-function defect, and the significant leftward shift of Ca2+ 
sensitivity was rescued (Lehnart et al., 2004). However, the mechanism of action of JTV519 is 
complex and conflicting. It was reported that JTV519 suppressed spontaneous Ca2+ release and 
inhibited [3H] ryanodine binding to Ryr2 irrespective of FKBP12.6 association (Hunt et al., 
2007). Recently, this drug was reported to be a Ca2+-dependent blocker of sarco/endoplasmic 
reticulum Ca2+-ATPase and partial agonist of RYRs (Darcy et al., 2016). 
Generally, rycals are designed to restore the normal function of RYR2 channels and are not 
RYR2 channel blockers. In this study, two candidate drugs for the CPVT treatment, rycal1 and 
rycal2, were provided by a pharmacological company.  
Rycal1 (Figure 35, Figure 36) and rycal2 (Figure 37, Figure 38) demonstrated antiarrhythmic 
effects on CPVT(a, b, c)-CMs harboring mutations R420W, A2254V, E4076K, respectively, but 
not on CPVTd-CMs with RYR2 mutation H4742Y. 
Taken together, CMs derived from CPVT-iPSCs display mutation-specific arrhythmogenesis 
features, and these profiles have a profound impact on antiarrhythmic drugs’ treatment. 
Moreover, the application of two electrophysiological methods exhibits a good example for 
studying drug effects in combination with iPSC technology. 
 
4.4 Differentially regulated cAMP dynamics in Ctrl-CMs and CPVT-CMs 
 
Due to the lack of in vitro specimen, the PDE activities have not been well investigated in human 
CMs (Mehel et al., 2013; Molina et al., 2012). To investigate if the cAMP levels are altered in 
cytosol or at the RYR2 microdomain in CPVT-CMs, FRET measurements were performed in 
Epac1-camps- or Epac1-camps-JNC expressing CMs, respectively. No existing empirical 
research addresses β-adrenergic signaling during the CPVT pathological remodeling by using 
iPSC-CMs. The results showed that even low concentration of ISO can induce FRET change in 
Epac1-camps- or Epac1-camps-JNC-expressing iPSC-CMs despite some immature features of 
iPSC-CMs (Figure 39). 
The FRET change in Epac1-camps-expressing CPVTa-CMs was significantly higher when 
compared to Ctrl-CMs, indicating that the cytosolic cAMP level is higher in CPVTa-CMs than in 





expressing CPVTb- and CPVTc-CMs was significantly higher when compared to Ctrl-CMs, 
indicating that the cAMP levels at the RYR2 microdomain are higher in these CPVT-CMs than 
in Ctrl-CMs after 10 nM ISO treatment. Interestingly, the FRET change in Epac1-camps-JNC-
expressing CPVTd-CMs was significantly lower when compared to Ctrl-CMs, indicating that the 
cAMP level at the RYR2 microdomain is lower in CPVTd-CMs than in Ctrl-CMs after 10 nM 
ISO treatment. These data may imply that the altered PKA activities in different CPVT-iPSC-
CMs with different RYR2 mutations. Currently, RYR2 has three well-defined phosphorylation 
sites, Ser2814, Ser2030 and Ser2808 although additional putative phosphorylation sites at 
Ser2810, Ser2811, Ser2797 and Thr2876 have been reported (Yuchi et al., 2012). Ser2030 and 
Ser2808 are mainly phosphorylated by PKA (Marx et al., 2000; Xiao et al., 2006). However, in 
our lab, high baseline phosphorylation of the RYR2 residue Ser2808 was found in both Ctrl- and 
CPVT(a, b, c)-CMs; and no patient-specific differences of the basal phosphorylation status was 
observed in CPVT(a, b, c)-CMs when compared to Ctrl-CMs (Henze, 2016). After ISO 
stimulation, phosphorylation of Ser2808 was slightly increased in CPVT-CMs and Ctrl-CMs, but 
mutation- or patient-specific differences were not observed (Henze, 2016), which might be due 
to the high baseline phosphorylation of the RYR2 residue Ser2808. Future study should 
investigate the phosphorylation status of the other RYR2 residues, which are mainly 
phosphorylated by PKA in CPVT(a, b, c)-CMs, and analyze the phosphorylation status of the 
RYR2 residues Ser2808 and Ser2030 in CPVTd-CMs. 
 
4.4.1 PDE2 and PDE3 activities are decreased in CPVT-CMs 
 
Abnormalities of β-adrenergic signaling have been well documented in DCM (Ahmet et al., 
2008; Lowes  et al., 2002). Recently, expression profiles and functional assays confirmed a 
significant upregulation of PDE subtypes PDE 2A and 3A in DCM iPSC-CMs (Wu et al., 2015). 
The PDE3A subfamily is proposed to be the most important cAMP-degrading PDE in human 
CMs. Interestingly, a recent report showed that PDE2 was markedly up-regulated in human 
failing hearts and desensitized β-AR against acute β-AR stimulation by using human and/or 
canine experimental heart failure (Mehel et al., 2013). There are several publications reported the 
decreasing of PDE3 activity and PDE3 protein levels in left ventricular endocardium in pacing-





There is little known about the relationship between the CPVT and the activities of PDE2 and 
PDE3. This is the first study to investigate the activities of PDE2 and PDE3 in CPVT-iPSC-CMs. 
The results revealed that the activities of PDE2 and PDE3 to degradate cAMP decreased no 
matter in cytosol or at the RYR2 compartment in CPVT(a, b, c, d)-CMs harboring mutations 
R420W, A2254V, E4076K and H4742Y, respecitively. Future studies should investigate 
expression levels of PDE2 and PDE3 in CPVT(a, b, c, d)-CMs at both RNA and protein levels. 
 
4.4.2 PDE4 activity shows mutation-specific properties in CPVT-CMs 
 
It was reported that PDE4 inhibition not only increased intracellular cAMP and L-type Ca2+ 
current and dramatically delayed their decay after a short adrenergic stimulation, but also 
increased the frequency of Ca2+ sparks at baseline, as well as the contractile response and the 
incidence of arrhythmias in human atrial strips during β-adrenergic stimulation (Molina et al., 
2012). Previous study reported that PDE4 partially protected the right ventricle against β-
adrenaline evoked arrhythmias (Galindo-Tovar and Kaumann, 2008). 
In this study, when iPSC-CMs were treated with 10 nM ISO, the inhibition of PDE4 caused big 
increases in cAMP levels that saturated both Epac1-camps and Epac1-camps-JNC sensors. 
Therefore, PDE4 inhibition was repeated after the treatment with 1 nM ISO to measure the 
dynamic range of the FRET sensors. These data indicate that PDE4 is the major regulator of 
cAMP level in iPSC-CMs after ISO stimulation and that PDE2 and PDE3 have a smaller 
contribution to regulate the cAMP level in cytosol and at the RYR2 compartment. Similar data 
have been reported in ventricular CMs after ISO stimulation, which were isolated from mice 
expressing Epac1-camps or Epac1-camps-JNC sensors (Götz, 2014). 
It was demonstrated that PDE4D3 and other key components of cAMP signaling (PKA and 
phosphatases) were associated with RYR2 via mAKAP and formed a cAMP microdomain that 
regulated RYR2 (Dodge et al., 2001; Lehnart, 2007; Lehnart et al., 2005). Furthermore, it was 
postulated that during heart failure, depletion of PDE4D3 from the microdomain led to PKA-






In this study, CPVT(b, c)-CMs, but not CPVT(a, d)-CMs, showed reduced activities of PDE4 in 
cytosol (Figure 44). However, the phosphorylation of RYR2 Ser2808 was not altered in CPVT(b, 
c)-iPSC-CMs after ISO stimulation (Henze, 2016). This could be explained by the previous 
suggestion that PKA is fully active, even at basal and unstimulated state (Beavo and Brunton, 
2002). 
It was reported that in adult ventricular CMs, global or basal cAMP level is ~1.2 µM (Iancu et al., 
2008), whereas the affinity of PKA is in the range of 10-100 nM in vitro. Further study is needed 
to figure out whether the phosphorylation status of other proteins important for calcium handling 
is altered in CPVT-CMs. In addition, it is necessary to analyze which PDE4 isoforms participate 
in mutation-specific CPVT arrhythmogenesis. 
Based on the FRET measurements in Epac1-camps-JNC, the RYR2 compartmental PDE4 
activity is reduced in CPVT(c, d)-CMs but not in CPVT(a, b)-CMs after ISO stimulation, when 
compared to Ctrl-CMs. However, the function of PDE4 in CPVT(c, d)-CMs is still unclear. It 
was hypothesized that local PDE4D3 activity might shape a pool of low cAMP concentrations at 
the cardiac RYR to protect the channel from excessive phosphorylation (Götz, 2014). In Ctrl-
CMs, β-adrenergic stimulation causes an increase in cAMP, strong enough to overcome the 
PDE4D3 barrier, to activate PKA for channel phosphorylation and Ca2+ gating to facilitate 
myocyte contraction. However, for CPVT-CMs, mutations in RYR2 may cause PDE4D3 
depletion, hyperphosphorylation and leaky RyR2 (increased Ca2+ gating during systole or 
diastole), which are associated with arrhythmias.  As mentioned above, further study is needed to 
figure out whether the phosphorylation status of other proteins important for calcium handling is 
altered in CPVT-CMs, how different PDEs play roles in arrhythmogenesis of CPVT, and 
whether the expression levels or locations are altered in CPVT-CMs. 
To my knowledge, this is the first research that focus on cAMP dynamic in CPVT pathology by 
combining the technologies of iPSC disease modeling and FRET. It implies that there are 
probably some connections between the altered activities of PDE2, 3, 4 and the distinguish 






4.5 Future perspectives 
 
Although these results strongly imply a domain- or mutation-specific pathophysiological 
mechanism in CPVT(a, b, c, d)-CMs harboring different RYR2 mutations, the calcium handling 
experiments (cytosolic and luminal calcium sensitivity of RYR2, SR calcium contents, the 
threshold of SOICR, etc.) should be applied to further figure out the exact differences in 
underlying mechanism between the non-transmembrane domain and the transmembrane domain 
mutation-caused CPVT.  
A powerful gene-editing technology of clustered regularly interspaced short palindromic repeats 
is the biggest game changer since PCR. It gives an opportunity to systematical and reliable 
disease modeling in relevant human cell types by a combination of iPSCs and gene editing 
technologies (Soldner and Jaenisch, 2012). It is worthy to use the powerful gene-editing tool to 
correct the specific RYR2 point mutations to figure out whether the disease phenotypes observed 
in this study are mutation-specific. 
Recently, epigenetic regulation has been shown to be related to HCM, DCM, and diabetic 
cardiomyopathy (Asrih and Steffens, 2013; Haas et al., 2013; Wu et al., 2015). It is a top priority 
to perform gene and protein expression profiling and to study epigenetic changes of PDE2, 
PDE3, and PDE4, which may help to figure out genetic CPVT pathological remodeling in the 
future. 
The potential strategy of direct conversion of human fibroblasts into functional CMs by small 
molecules would shorten the timeline for disease modeling.  
Since the complexities of the RYR2 channel and its binding proteins, domain-specific 
mechanisms are not enough to summarize all the mutations. In the personalized medicine era, the 
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